JP2013530239A - Quinolines as PI3K inhibitors - Google Patents

Abstract

【選択図】なしPI3K (phosphatidylinositol 3-kinase for the treatment of systemic inflammation, arthritis, rheumatic diseases, osteoarthritis inflammatory bowel disorders, inflammatory eye disorders, inflammation or unstable bladder disorders, psoriasis, skin diseases with inflammatory components, chronic inflammatory conditions -Δ) Compounds of structure that are selective inhibitors.

[Selection figure] None

Description

  This application claims priority to US Provisional Patent Application No. 61 / 360,262, filed June 30, 2010, which is incorporated herein by reference.

  The present invention relates generally to phosphatidylinositol 3-kinase (PI3K) enzymes, and more specifically to selective inhibitors of PI3K activity and methods of using such substances.

  Cell signaling via 3′-phosphated phosphoinositides has been suggested in various cellular processes such as malignant tumor transformation, growth factor signaling, inflammation, and immunity (for a review, see Rameh et al., J. Biol. Biol Chem, 274: 8347-8350 (1999)). Phosphatidylinositol 3-kinase (PI3 kinase; PI3K), an enzyme involved in the production of these phosphorylated signaling products, is a growth factor receptor tyrosine kinase and inositol that phosphorylates the viral tumor protein, phosphatidylinositol (PI). Originally identified as activity for its phosphorylated derivative at the 3′-hydroxyl position of the ring (Panayotou et al., Trends Cell Biol 2: 358-60 (1992)).

Phosphatidylinositol-3,4,5-triphosphate (PIP3) levels, the major product of PI3 kinase activation, increase when cells are treated with various stimuli. This includes signaling through most growth factors and receptors for many inflammatory stimuli, hormones, neurotransmitters and antigens, thus activation of PI3K, if not the highest frequency, on the mammalian cell surface Represents signal transduction events for receptor activation (Cantley, Science 296: 1655-1657 (2002); Vanhaesbroeck et al. Annu. Rev. Biochem, 70: 535-602 (2001)). Thus, PI3 kinase activation has been implicated in a wide range of cellular responses such as cell growth, migration, differentiation, and apoptosis (Parker et al., Current Biology, 5: 577-99 (1995); Yao et al. , Science, 267: 2003-05 (1995)). Although the downstream targets of phospholipids generated after PI3 kinase activation are not well characterized, pleckstrin homology (PH) domains and FYVE finger domain-containing proteins are active upon binding to various phosphatidylinositol lipids (Sternmark et al., J Cell Sci, 112: 4175-83 (1999); Lemmon et al., Trends Cell Biol, 7: 237-42 (1997)). Two groups of PI3K effectors containing PH domains have been studied in the context of immune cell signaling, they are tyrosine kinase TEC family members and AGC family serine / threonine kinases. It has a clear selectivity for PtdIns (3,4,5) _{P 3,} as the Tec family members including PH domain, Tec, Btk, include Itk and Etk. The binding of PH to PIP ₃ is important in the tyrosine kinase activity of Tec family members (Schaeffer and Schwartzberg, Curr. Opin. Immunol. 12: 282-288 (2000)). AGC family members regulated by PI3K include phosphoinositide-dependent kinase (PDK1), AKT (also referred to as PKB) and certain isoforms of protein kinase C (PKC) and S6 kinase. There are three isoforms of AKT, and activation of AKT is closely related to PI3K-dependent growth and survival signals. Activation of AKT depends on phosphorylation by PDK1, which also has a 3-phosphoinositide-selective PH domain and recruits it to the membrane where it interacts with AKT. Other important PDK1 substrates are PKC and S6 kinase (Deane and Fruman, Annu. Rev. Immunol. 22_563-598 (2004)). In vitro, some isoforms of protein kinase C (PKC) are directly activated by PIP3. (Burgering et al., Nature, 376: 599-602 (1995)).

  Currently, the PI3 kinase enzyme family is classified into three classes based on substrate specificity. Class I PI3K phosphorylates phosphatidylinositol (PI), phosphatidylinositol-4-phosphate, and phosphatidyl-inositol-4,5-biphosphate (PIP2) to give phosphatidylinositol-3-phosphate (PIP), phosphatidyl, respectively. Inositol-3,4-biphosphate and phosphatidylinositol-3,4,5-triphosphate can be produced. Class II PI3K phosphorylates PI and phosphatidyl-inositol-4-phosphate, whereas class III PI3K can only phosphorylate PI.

  Initial purification and molecular cloning of PI3 kinase showed that PI3 kinase was a heterodimer composed of p85 and p110 subunits (Otsu et al., Cell, 65: 91-104 (1991); Hiles et al., Cell, 70: 419-29 (1992)). Since then, four different class I PI3Ks, each consisting of a different 110 kDa catalytic subunit and regulatory subunit, have been identified and named PI3Kα, β, δ, and γ. More specifically, the three catalytic subunits, p110α, p110β, and p110δ each interact with the same regulatory subunit p85, while p110γ interacts with a different regulatory subunit p101. As described below, the expression patterns of these PI3Ks in human cells and tissues are also different. Although a wealth of information on the general cellular function of PI3 kinase has been accumulated to date, the role played by individual isoforms is not well understood.

  The cloning of bovine p110α has been described. This protein was identified to be related to Saccharomyces cerevisiae protein: Vps34p, a protein involved in the vacuolar protein process. Recombinant p110α product was also shown to be associated with p85α, resulting in PI3K activity in transfected COS-1 cells. Hiles et al. , Cell, 70, 419-29 (1992).

  For the cloning of a second human p110 isoform designated p110β, see Hu et al. Mol Cell Biol, 13: 7677-88 (1993). This isoform is associated with intracellular p85, with a number of p110β mRNA in human and mouse tissues and human umbilical vein endothelial cells, Jurkat human leukemic T cells, 293 human fetal kidney cells, mouse 3T3 fibroblasts, HeLa cells, And is found to be ubiquitously expressed in NBT2 rat bladder cancer cells. Such extensive expression suggests that this isoform is broadly important in signal transduction pathways.

  For identification of the p110δ isoform of PI3 kinase, see Chantry et al. , J Biol Chem, 272: 19236-41 (1997). The human p110δ isoform was observed to be expressed in a tissue-limited format. The human p110δ isoform is expressed at high levels in lymphocytes and lymphoid tissues and has been shown to play an important role in PI3 kinase-mediated signaling of the immune system (Al-Alwan etl al. JI 178). : 2328-2335 (2007); Okkenhaug et al JI, 177: 5122-5128 (2006); Lee et al. PNAS, 103: 1289-1294 (2006)). P110δ has also been shown to be expressed at lower levels in breast cells, melanocytes and endothelial cells (Vogt et al. Virology, 344: 131-138 (2006) and has since been selective for breast cancer cells). (Sawyer et al. Cancer Res. 63: 1667-1675 (2003)) For details on the P110δ isoform, see US Patent Application No. 5,858,753; And 5,985, 589. Vanhasebroeck et al., Proc Nat. Acad Sci USA, 94: 4330-5 (1997), and the international publication WO97 / See also 46688.

  In each of the PI3Kα, β, and δ subtypes, the p85 subunit directs PI3 kinase to the plasma membrane by interacting with its SH2 domain and phosphorylated tyrosine residues (present in the proper sequence relationship) in the target protein. It acts to localize (Rameh et al., Cell, 83: 821-30 (1995)). Five isoforms of p85 encoded by three genes have been identified (p85α, p85β, p55γ, p55α and p50α). Alternative transcripts of the Pik3r1 gene encode p85α, p55α and p50α proteins (Deane and Fruman, Annu. Rev. Immunol. 22: 563-598 (2004)). p85α is ubiquitously expressed, while p85β is found primarily in brain and lymphoid tissues (Volinia et al., Oncogene, 7: 789-93 (1992)). The relationship of the p85 subunit to the PI3 kinase p110α, β, or δ catalytic subunit appears to be necessary for the catalytic activity and stability of these enzymes. In addition, Ras protein binding also upregulates PI3 kinase activity.

p110γ cloning showed additional complexity within the PI3K family of enzymes (Stoyanov et al., Science, 269: 690-93 (1995)). The p110γ isoform is closely related to p110α and p110β (45-48% identical to the catalytic domain), but does not utilize p85 as the target subunit, as described. Instead, p110γ binds to the p101 regulatory subunit that also binds to the βγ subunit of the heterotrimeric G protein. The p101 regulatory subunit of PI3Kγ was originally cloned in pigs and subsequently a human homologous molecular species was identified (Krugmann et al., J Biol Chem, 274: 17152-8 (1999)). The interaction between the N-terminal region of p101 and the N-terminal region of p110γ is known to activate PI3Kγ via Gβγ. Recently, p84 ^homologue, p84 or p87 ^PIKAP (87 ^kDa PI3Kγ adapter protein) that binds to p110γ has been identified (Voigt et al. JBC, 281: 9777-9986 (2006), Suire et al. Curr. Biol. 15 : 566-570 (2005)). p87 ^PIKAP is homologous to p101 in the region that binds p110γ and Gβγ and also mediates activation of the G protein-coupled receptor downstream of p110γ. Unlike p101, p87 ^PIKAP is highly expressed in the heart and may be important in PI3Kγ cardiac function.

  Constitutively active PI3K polypeptides are described in the international publication WO 96/25488. This publication discloses the preparation of a chimeric fusion protein in which a 102-residue fragment of p85, known as the inter-SH2 (iSH2) region, is fused via a linker region to the N-terminus of mouse p110. The p85iSH2 domain can clearly activate PI3K activity in a manner equivalent to intact p85 (Klippel et al., Mol Cell Biol, 14: 2675-85 (1994)).

  Thus, PI3 kinases can be defined by their amino acid identity or by their activity. Additional members of this growing gene family include distant interspecies lipid and protein kinases (such as Saccharomyces cerevisiae Vps34 TOR1, and TOR2) (and their mammalian homologs such as FRAP and mTOR), telangiectasia ataxia Examples include the gene product (ATR) and the catalytic subunit of DNA-dependent protein kinase (DNA-PK). See generally Hunter, Cell, 83: 1-4 (1995).

  PI3 kinase is also involved in several aspects of leukocyte activation. p85-related PI3 kinase activity has been shown to be physically related to the cytoplasmic domain of CD28, a costimulatory molecule important in T cell activation in antigenic responses (Pages et al., Nature, 369: 327). -29 (1994); Rudd, Immunity, 4: 527-34 (1996)). Activation of T cells via CD28 reduces the activation threshold by the antigen and increases the magnitude and duration of the proliferative response. These effects are associated with an increase in several gene transcripts, including an important T cell growth factor, interleukin-2 (IL2) (Fraser et al., Science, 251: 313-16 (1991)). Mutations in CD28 that render it no longer able to interact with PI3 kinase result in unsuccessful initiation of IL2 production, suggesting an important role for PI3 kinase in T cell activation.

Specific inhibitors of each member of the enzyme family provide a valuable tool for the decoding of each enzyme function. Two compounds, LY294002 and wortmannin, are widely used as PI3 kinase inhibitors. However, these compounds are non-specific PI3K inhibitors because they do not distinguish the four members of class I PI3 kinase. For example, wortmannin IC ₅₀ values for each of the various class I PI3 kinases range from 1 to 10 nM. Similarly, the IC ₅₀ value of LY294002 for each of these PI3 kinases is approximately 1 μM (Fruman et al., Ann Rev Biochem, 67: 481-507 (1998)). Therefore, the use of these compounds in the study of the role of each class I PI3 kinase is limited.

  Based on studies using wortmannin, there is evidence that PI3 kinase function is also required for some aspects of leukocyte signaling through G protein-coupled receptors (Thelen et al., Proc Natl Acad Sci USA, 91). : 4960-64 (1994)). Furthermore, wortmannin and LY294002 have been shown to prevent neutrophil migration and superoxide release. However, since these compounds do not distinguish between the various isoforms of PI3K, which particular PI3K isoform (s) are involved in these phenomena and which functions of different class I PI3K enzymes are generally normal tissue It remains unclear from these studies whether it works in both diseased and diseased tissues. Co-expression of several PI3K isoforms in most tissues has, until recently, confused attempts to distinguish each enzyme activity.

Recently, along with the development of genetically engineered mice capable of testing isoform-specific knockout mice and kinase dead knock-in mice and the development of inhibitors selective by some different isoforms, the distinction of various PI3K isozyme activities is progressing. . P110α and p110β knockout mice have been generated, both of which have high fetal mortality and little information on the expression and function of p110α and β available from these mice (Bi et al. Mamm. Genome, 13 169-172 (2002); Bi et al. J. Biol. Chem. 274: 10963-10968 (1999)). More recently, a p110α kinase dead knock-in mouse (p110αD ^933A ) with a single point mutation in the DFG motif in the ATP binding pocket was generated that impairs kinase activity but retains mutant p110α kinase expression. Compared to knockout mice, the knockin approach retains signaling complex stoichiometry, scaffold function, and mimics the small molecule approach more realistically than knockout mice. Similar to ^p110αKO mice, fetal mortality in ^p110αD933A homozygous mice is high. However, although heterozygous mice are viable and fertile, they exhibit severe signal transduction via insulin receptor substrate (IRS) protein, the major mediator of insulin, insulin-like growth factor 1 and leptin action. Insufficiency to these hormones causes hyperinsulinemia, glucose intolerance, bulimia, increased adiposity and decreased overall heterozygote growth (Foukas, et al. Nature, 441: 366) 370 (2006)). These studies demonstrated a non-redundant role for p110α as an intermediate in IGF-1, insulin, and leptin signaling that was not substituted by other isoforms. We will have to wait for details of the p110β kinase dead knock-in mouse to further understand this isoform function (the mouse has been made but has not yet been published; Vanhaesebroeck).

  Both P110γ knockout mice and kinase dead knockin mice have been generated and generally display similar and mild phenotypes with major defects in innate immune system cell migration and T cell thymine expression defects (Li et al. Science, 287: 1046-1049 (2000), Sasaki et al. Science, 287: 1040-1046 (2000), Patrucco et al. Cell, 118: 375-387 (2004)).

Similar to p110γ, PI3Kδ knockout mice and kinase dead knockin mice have been generated and can survive with mild and similar phenotypes. p110δ ^D910A mutant knock-in mice have shown a critical role in B cell and T cell antigen receptor signaling, B cell δ expression and function, almost undetectable by borderline B cells and CD5 + B1 cells (Clayton et al. J. Exp. Med. 196: 753-763 (2002); Okenhaug et al. Science, 297: 1031-1034 (2002)). The p110δ ^D910A mouse has been extensively studied and the various roles that δ plays in the immune system have been elucidated. T cell-dependent and T cell-independent immune responses are greatly reduced in p110δ ^D910A , and ^secretion of TH1 (INF-γ) and TH2 cytokines (IL-4, IL-5) is impaired (Okkenhaug et al. al., J. Immunol., 177: 5122-5128 (2006)). Recently, human patients with the p110δ mutation have been described. A Taiwanese boy presenting with major B-cell immunodeficiency and hypogammaglobulinemia whose cause has been unknown until now is m.p. in the codon 1021 of exon 24 of p110δ. A single base pair substitution from 3256G to A was exhibited. This mutation caused a missense amino acid substitution (E to K) at codon position 1021, located in the highly conserved catalytic domain of the p110δ protein. To the extent studied, no other mutations have been identified in this patient, and his phenotype is consistent with p110δ deficiency in mice (Jou et al. Int. J. Immunogenet. 33: 361-369 (2006). )).

  Isoform-selective small molecule compounds have been developed and have found various successes in all class I PI3 kinase isoforms (Ito et al. J. Pharm. Exp. Therapeut., 321: 1-8 (2007 )). Since the p110α mutation has been identified in several solid tumors, α inhibitors are desirable; for example, α amplification mutations are related to 50% of ovarian, cervical, lung and breast cancer, and activation mutations are the intestinal 50 % And breast cancer 25% (Hennessy et al. Nature Reviews, 4: 988-1004 (2005)). Yamanouchi has developed compound YM-024, which inhibits α and δ with equal potency and is 8- and 28-fold selective for β and γ, respectively (Ito et al. J. Pharm. Exp. Therapeut. , 321: 1-8 (2007)).

  P110β is involved in thrombus formation (Jackson et al. Nature Med. 11: 507-514 (2005)) and a small molecule inhibitor specific to this isoform was later considered for coagulation disorder related indications. (TGX-221: 0.007 μM on β; 14-fold selective for δ and over 500-fold selective for γ and α) (Ito et al. J. Pharm. Exp. Therapeut., 321: 1 -8 (2007)).

  p110γ selective compounds have been developed by several groups as immunosuppressants for autoimmune diseases (Rueckle et al. Nature Reviews, 5: 903-918 (2006)). Of note, AS605240 is effective in the rheumatoid arthritis mouse model (Camps et al. Nature Medicine, 11: 936-943 (2005)) and delays disease onset in the systemic lupus erythematosus model (Barber et al. Nature Medicine, 11: 933-935 (205)).

δ selective inhibitors have also been recently described. Most selective compounds include quinazoline purine inhibitors (PIK39 and IC87114). IC87114 inhibits p110δ in the high nanomolar range (three digits) and is 100 times more selective than p110α and 52 times more selective than p110β, but lacks selectivity with p110γ. (About 8 times). This shows no activity against any of the protein kinases tested (Knight et al. Cell, 125: 733-747 (2006)). In addition to using δ-selective compounds or genetically engineered mice (p110δ ^D910A ) to play an important role in B and T cell activation, δ is a well-received neutrophil migrating and ^{primed prime.} It has also been shown to be partially involved in the neutrophil respiratory burst, causing partial blocking of antigen-IgE-mediated mast cell degranulation (Condiffe et al. Blood, 106: 1432-1440 (2005); Ali et al. Nature, 431: 1007-1011 (2002)). Thus, p110δ is becoming an important mediator of many major inflammatory responses that are also known to be involved in abnormal inflammatory conditions, including but not limited to autoimmune diseases and allergies. To support this concept, an increasing number of p110δ target validation data derived from multiple studies using both genetic tools and pharmacological agents is increasing. Therefore, using δ-selective compound IC 87114 and p110δ ^D910A mice, Ali et al. (Nature, 431: 1007-1011 (2002)) showed that δ plays an important role in an allergic disease mouse model. In the absence of functioning δ, passive cutaneous anaphylaxis (PCA) is significantly reduced and may contribute to allergen IgE-induced mast cell activation and reduced degranulation. In addition, inhibition of δ with IC 87114 has been shown to significantly alleviate inflammation and disease in an asthmatic mouse model using ovalbumin-induced airway inflammation (Lee et al. FASEB, 20: 455-). 465 (2006) These data utilizing compounds were supported in p110δ ^D910A mutant mice using the same allergic airway inflammation model by different groups (Nashed et al. Eur. J. Immunol. 37: 416-424). (2007)).

  There is a need for further characterization of PI3Kδ function in inflammatory and autoimmune environments. Furthermore, understanding PI3Kδ requires further details regarding the structural interactions of p110δ with its regulatory subunits and other proteins in the cell. In order to avoid the potential toxicity associated with isozyme p110α (insulin signaling) and β (platelet activation) activity, more potent, selective or specific inhibitors of PI3Kδ are still needed. In particular, selective or specific inhibitors of PI3Kδ are desired for further exploration of the role of this isozyme and for the development of better drugs that modulate isozyme activity.

US Pat. No. 5,858,753 US Pat. No. 5,822,910 US Pat. No. 5,985,589 International Publication No. 97/46688 International Publication No. 96/25488

Rameh et al. , J. et al. Biol Chem, 274: 8347-8350 (1999) Panayotou et al. , Trends Cell Biol 2: 358-60 (1992). Cantley, Science 296: 1655-1657 (2002) Vanhaesebroeck et al. Annu. Rev. Biochem, 70: 535-602 (2001) Parker et al. , Current Biology, 5: 577-99 (1995). Yao et al. , Science, 267: 2003-05 (1995). Starnmark et al. J Cell Sci, 112: 4175-83 (1999). Lemmon et al. , Trends Cell Biol, 7: 237-42 (1997). Schaeffer and Schwartzberg, Curr. Opin. Immunol. 12: 282-288 (2000) Deane and Fruman, Annu. Rev. Immunol. 22_563-598 (2004) Burgering et al. , Nature, 376: 599-602 (1995). Otsu et al. Cell, 65: 91-104 (1991). Hiles et al. Cell, 70: 419-29 (1992). Hu et al. Mol Cell Biol, 13: 7677-88 (1993). Chantry et al. , J Biol Chem, 272: 19236-41 (1997). Al-Alwan et al al. JI 178: 2328-2335 (2007) Okenhaug et al. J. et al. Immunol. 177: 5122-5128 (2006) Lee et al. PNAS, 103: 1299-1294 (2006) Vogt et al. Virology, 344: 131-138 (2006) Sawyer et al. Cancer Res. 63: 1667-1675 (2003) Vanhaesebroeck et al. , Proc Nat. Acad Sci USA, 94: 4330-5 (1997) Rameh et al. Cell, 83: 821-30 (1995). Volinia et al. , Oncogene, 7: 789-93 (1992). Stoyanov et al. , Science, 269: 690-93 (1995). Krugmann et al. , J Biol Chem, 274: 17152-8 (1999). Voigt et al. JBC, 281: 9777-9986 (2006) Suire et al. Curr. Biol. 15: 566-570 (2005) Klippel et al. Mol Cell Biol, 14: 2675-85 (1994). Hunter, Cell, 83: 1-4 (1995) Pages et al. , Nature, 369: 327-29 (1994). Rudd, Immunity, 4: 527-34 (1996) Fraser et al. , Science, 251: 313-16 (1991) Fruman et al. , Ann Rev Biochem, 67: 481-507 (1998). Thelen et al. Proc Natl Acad Sci USA, 91: 4960-64 (1994). Bi et al. Mamm. Genome, 13: 169-172 (2002) Bi et al. J. et al. Biol. Chem. 274: 10963-10968 (1999) Foukas, et al. Nature, 441: 366-370 (2006) Li et al. Science, 287: 1046-1049 (2000) Sasaki et al. Science, 287: 1040-1046 (2000). Patrucco et al. Cell, 118: 375-387 (2004) Clayton et al. J. et al. Exp. Med. 196: 753-763 (2002) Okenhaug et al. Science, 297: 1031-1034 (2002). Jou et al. Int. J. et al. Immunogenet. 33: 361-369 (2006) Ito et al. J. et al. Pharm. Exp. Therapeut. , 321: 1-8 (2007) Hennessy et al. Nature Reviews, 4: 988-1004 (2005). Jackson et al. Nature Med. 11: 507-514 (2005) Rueckle et al. Nature Reviews, 5: 903-918 (2006). Camps et al. Nature Medicine, 11: 936-943 (2005). Barber et al. Nature Medicine, 11: 933-935 (205). Knight et al. Cell, 125: 733-747 (2006) Condiffe et al. Blood, 106: 1432-1440 (2005) Ali et al. Nature, 431: 1007-1011 (2002) Lee et al. FASEB, 20: 455-465 (2006) Nashed et al. Eur. J. et al. Immunol. 37: 416-424 (2007)

  The present invention is a general formula useful for inhibiting the biological activity of human PI3Kδ.

の化合物の新規クラスを含む。本発明の別の態様は、ＰＩ３Ｋδを選択的に阻害しつつ他のＰＩ３Ｋイソ型に対して相対的に低い阻害能を有する化合物を提供することである。本発明の別の態様は、ヒトＰＩ３Ｋδ機能を特徴付ける方法を提供することである。本発明の別の態様は、ヒトＰＩ３Ｋδ活性を選択的に調節し、それにより、ＰＩ３Ｋδ機能障害に媒介される疾患の医学的治療を促進する方法を提供することである。本発明の他の態様および利点は、当業者に容易に明らかであろう。

A new class of compounds. Another aspect of the present invention is to provide compounds that have a relatively low inhibitory potency against other PI3K isoforms while selectively inhibiting PI3Kδ. Another aspect of the invention is to provide a method for characterizing human PI3Kδ function. Another aspect of the present invention is to provide a method for selectively modulating human PI3Kδ activity, thereby facilitating medical treatment of diseases mediated by PI3Kδ dysfunction. Other aspects and advantages of the invention will be readily apparent to those skilled in the art.

  One aspect of the present invention is:

の構造の化合物もしくはその任意の医薬上許容可能な塩に関し、式中：
Ｘ^２はＣ（Ｒ^４）もしくはＮであり；
Ｘ^３はＣ（Ｒ^５）もしくはＮであり；
Ｘ^４はＣ（Ｒ^５）もしくはＮであり；
Ｘ^５はＣ（Ｒ^４）もしくはＮであり；ここで前記Ｘ^２、Ｘ^３、Ｘ^４およびＸ^５のうち２つより多くがＮであることはなく；
ＹはＮＲ^７、ＣＲ^ａＲ^ａ、ＳもしくはＯであり；
ｎは０、１、２もしくは３であり；
Ｒ^１は、Ｈ、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＣＯ_２Ｒ^ａ、−ＮＲ^ａＣ_２〜６アルキルＳＯ_２Ｒ^ｂ、−ＣＨ_２Ｃ（＝Ｏ）Ｒ^ａ、−ＣＨ_２Ｃ（＝Ｏ）ＯＲ^ａ、−ＣＨ_２Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＣＨ_２Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＣＨ_２ＯＲ^ａ、−ＣＨ_２ＯＣ（＝Ｏ）Ｒ^ａ、−ＣＨ_２ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＣＨ_２ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＣＨ_２ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＣＨ_２ＯＣ_２〜６アルキルＯＲ^ａ、−ＣＨ_２ＳＲ^ａ、−ＣＨ_２Ｓ（＝Ｏ）Ｒ^ａ、−ＣＨ_２Ｓ（＝Ｏ）_２Ｒ^ｂ、−ＣＨ_２Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＣＨ_２Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−ＣＨ_２Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−ＣＨ_２Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＣＨ_２ＮＲ^ａＲ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＣＨ_２Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＣＨ_２ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＣＨ_２ＮＲ^ａＣ_２〜６アルキルＯＲ^ａ、−ＣＨ_２ＮＲ^ａＣ_２〜６アルキルＣＯ_２Ｒ^ａおよび−ＣＨ_２ＮＲ^ａＣ_２〜６アルキルＳＯ_２Ｒ^ｂから選択されるか；またはＲ^１は、Ｎ、ＯおよびＳから選択される０、１、２、３もしくは４個の原子を含むが、ＯもしくはＳ原子は１個より多く含むことはない、直接結合、Ｃ_１〜４アルキル結合、ＯＣ_１〜２アルキル結合、Ｃ_１〜２アルキルＯ結合、Ｎ（Ｒ^ａ）結合もしくはＯ結合した飽和、部分飽和もしくは不飽和３、４、５、６もしくは７員単環または８、９、１０もしくは１１員二環であり、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから独立して選択される０、１、２もしくは３個の置換基により置換され、前記環の利用可能な炭素原子は、追加的に０、１もしくは２個のオキソもしくはチオキソ基により置換され、前記環は、追加的にフェニル、ピリジル、ピリミジル、モルホリノ、ピペラジニル、ピペラジニル、ピロリジニル、シクロペンチル、シクロヘキシルから選択される０もしくは１個の直接結合、ＳＯ_２結合、Ｃ（＝Ｏ）結合またはＣＨ_２結合基により置換され、これらはすべて、さらにハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、および−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａから選択される０、１、２もしくは３基により置換され；
Ｒ^２は、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから選択され；
Ｒ^３は、Ｎ、ＯおよびＳから選択される０、１、２、３もしくは４個の原子を含むが、ＯもしくはＳは１個より多く含むことはない、飽和、部分飽和もしくは不飽和５、６もしくは７員単環または８、９、１０もしくは１１員二環から選択され、前記環の利用可能な炭素原子は、０、１もしくは２個のオキソもしくはチオキソ基により置換され、前記環は、０もしくは１個のＲ^２置換基により置換され、環は、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから独立して選択される０、１、２もしくは３個の置換基によりさらに置換されるか；またはＲ^３は、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから選択され；
Ｒ^４は、各場合において、独立して、Ｈ、ハロ、ニトロ、シアノ、Ｃ_１〜４アルキル、ＯＣ_１〜４アルキル、ＯＣ_１〜４ハロアルキル、ＮＨＣ_１〜４アルキル、Ｎ（Ｃ_１〜４アルキル）Ｃ_１〜４アルキル、Ｃ（＝Ｏ）ＮＨ_２、Ｃ（＝Ｏ）ＮＨＣ_１〜４アルキル、Ｃ（＝Ｏ）Ｎ（Ｃ_１〜４アルキル）Ｃ_１〜４アルキル、Ｎ（Ｈ）Ｃ（＝Ｏ）Ｃ_１〜４アルキル、Ｎ（Ｃ_１〜４アルキル）Ｃ（＝Ｏ）Ｃ_１〜４アルキル、Ｃ_１〜４ハロアルキル、もしくはＮ、ＯおよびＳから選択される０、１、２、３もしくは４個の原子を含むが、ＯもしくはＳは１個より多く含むことはない、不飽和５、６もしくは７員単環であり、ハロ、Ｃ_１〜４アルキル、Ｃ_１〜３ハロアルキル、−ＯＣ_１〜４アルキル、−ＮＨ_２、−ＮＨＣ_１〜４アルキル、−Ｎ（Ｃ_１〜４アルキル）Ｃ_１〜４アルキルから選択される０、１、２もしくは３個の置換基により置換され；
Ｒ^５は、各場合において、独立して、Ｈ、ハロ、ニトロ、シアノ、Ｃ_１〜４アルキル、ＯＣ_１〜４アルキル、ＯＣ_１〜４ハロアルキル、ＮＨＣ_１〜４アルキル、Ｎ（Ｃ_１〜４アルキル）Ｃ_１〜４アルキルもしくはＣ_１〜４ハロアルキルであり；
Ｒ^６は、Ｎ、ＯおよびＳから選択される０、１、２、３もしくは４個の原子を含むが、ＯもしくはＳは１個より多く含むことはない、飽和、部分飽和もしくは不飽和５、６もしくは７員単環または８、９、１０もしくは１１員二環から選択され、前記環の利用可能な炭素原子は、０、１もしくは２個のオキソもしくはチオキソ基により置換され、前記環は、０もしくは１個のＲ^２置換基により置換され、環は、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから独立して選択される０、１、２もしくは３個の置換基によりさらに置換されるか；またはＲ^６は、Ｈ、ハロ、Ｃ_１〜６アルキル、Ｃ_１〜４ハロアルキル、シアノ、ニトロ、−Ｃ（＝Ｏ）Ｒ^ａ、−Ｃ（＝Ｏ）ＯＲ^ａ、−Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−ＯＲ^ａ、−ＯＣ（＝Ｏ）Ｒ^ａ、−ＯＣ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＯＣ（＝Ｏ）Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−ＯＣ_２〜６アルキルＮＲ^ａＲ^ａ、−ＯＣ_２〜６アルキルＯＲ^ａ、−ＳＲ^ａ、−Ｓ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｓ（＝Ｏ）_２Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＯＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝Ｏ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｃ（＝ＮＲ^ａ）ＮＲ^ａＲ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２Ｒ^ａ、−Ｎ（Ｒ^ａ）Ｓ（＝Ｏ）_２ＮＲ^ａＲ^ａ、−ＮＲ^ａＣ_２〜６アルキルＮＲ^ａＲ^ａおよび−ＮＲ^ａＣ_２〜６アルキルＯＲ^ａから選択され；
Ｒ^７は、Ｈ、Ｃ_１〜６アルキル、−Ｃ（＝Ｏ）Ｎ（Ｒ^ａ）Ｒ^ａ、−Ｃ（＝Ｏ）Ｒ^ｂもしくはＣ_１〜４ハロアルキルであり；
Ｒ^ａは、各場合で、独立して、ＨもしくはＲ^ｂであり；ならびに
Ｒ^ｂは、各場合で、独立して、フェニル、ベンジルもしくはＣ_１〜_６アルキルであり、フェニル、ベンジルおよびＣ_１〜６アルキルは、ハロ、Ｃ_１〜４アルキル、Ｃ_１〜３ハロアルキル、−ＯＣ_１〜４アルキル、−ＮＨ_２、−ＮＨＣ_１〜４アルキル、−Ｎ（Ｃ_１〜４アルキル）Ｃ_１〜４アルキルから選択される０、１、２もしくは３個の置換基により置換されている。

For a compound of the structure or any pharmaceutically acceptable salt thereof:
X ² is C (R ⁴ ) or N;
X ³ is C (R ⁵ ) or N;
X ⁴ is C (R ⁵ ) or N;
X ⁵ is C (R ⁴ ) or N; wherein no more than ^two of said X ² , X ³ , X ⁴ and X ⁵ are N;
Y is NR ⁷ , CR ^a R ^a , S or O;
n is 0, 1, 2 or 3;
R ¹ is H, halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O ) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^{a) C (= O) OR} a, -N (R a) ^{(= O) NR a R a} , -N (R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a , —NR ^a C _2-6 alkyl OR ^a , —NR ^a C _2-6 alkyl CO ₂ R ^a , —NR ^a C _{2 6} alkyl _{^{SO 2 R b, -CH 2 C}} (= O) R a, -CH 2 C (= O) OR a, -CH 2 C (= O) NR a R a, -CH 2 C (= NR ^a ) NR ^a R ^a , —CH ₂ OR ^a , —CH ₂ OC (═O) R ^a , —CH ₂ OC (═O) NR ^a R ^a , —CH ₂ OC (═O) N (R ^a ) _{^{S (= O) 2 R a}} , -CH 2 OC 2~6 alkyl _{^{NR a R a, -CH 2 OC}} 2~6 alkyl _{^{OR a, -CH 2 SR a,}} - _{^{H 2 S (= O) R}} a, -CH 2 S (= O) 2 R b, -CH 2 S (= O) 2 NR a R a, -CH 2 S (= O) 2 N (R a) C (═O) R ^a , —CH ₂ S (═O) ₂ N (R ^a ) C (═O) OR ^a , —CH ₂ S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —CH ₂ NR ^a R ^a , —CH ₂ N (R ^a ) C (═O) R ^a , —CH ₂ N (R ^a ) C (═O) OR ^a , —CH ₂ N (R ^a ) C (═O) NR ^a R ^a , —CH ₂ N (R ^a ) C (═NR ^a ) NR ^a R ^a , —CH ₂ N (R ^a ) S (═O) ₂ R ^a , —CH ₂ N (R ^a ) S (═O) ₂ NR ^a R ^a , —CH ₂ NR ^a C _2-6 alkyl NR ^a R ^a , —CH ₂ NR ^a C _2-6 alkyl OR ^a , —CH ₂ NR ^a C _2-6 alkyl CO ₂ R ^a and —CH ₂ NR ^a C _2-6 alkyl SO ₂ R ^b ; or R ¹ is selected from 0, 1, 2, 3 or 4 selected from N, O and S Includes atoms but no more than one O or S atom, direct bond, C _1-4 alkyl bond, OC _1-2 alkyl bond, C _1-2 alkyl O bond, N (R ^a ) bond Or O-linked saturated, partially saturated or unsaturated 3, 4, 5, 6 or 7-membered monocyclic or 8, 9, 10 or 11-membered bicyclic, halo, C _1-6 alkyl, C _1-4 haloalkyl , Cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , ^{-OC (= O) R a,} -OC (= O) NR a R a, -OC (= O _{^{N (R a) S (=}} O) 2 R a, -OC 2~6 alkyl _^NR a ^R _{a, -OC} ^2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S ( ═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 0,1 independently selected from alkyl OR ^a, Or substituted by 3 substituents, where available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or thioxo groups, and the ring is additionally phenyl, pyridyl, pyrimidyl Substituted by 0 or 1 direct bond selected from morpholino, piperazinyl, piperazinyl, pyrrolidinyl, cyclopentyl, cyclohexyl, SO ₂ bond, C (═O) bond or CH ₂ bond group, all of which are further halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R substituted by 0, 1, 2, or 3 groups selected from: ^a , —NR ^a R ^a , and —N (R ^a ) C (═O) R ^a ;
R ² is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S ( ═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , _{^{-S (= O) 2 NR a}} R a, -S (= O) 2 N (R a) C (= O) R a, -S (= O) 2 N (R a) C (= O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) ^{C (= O) OR a,} -N (R a) C ( ^{O) NR a R a, -N} (R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) Selected from ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ³ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but no more than 1 O or S, saturated, partially saturated or unsaturated 5 , 6 or 7 membered monocyclic ring or 8, 9, 10 or 11 membered bicyclic ring, wherein available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, Substituted with 0 or 1 R ² substituents, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S ( ═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a independently selected from 0, 1, 2, or 3 substituents Further substituted; or R ³ is , Halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (= NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S ( ═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , − S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (= ^{O) OR a, -N (R} a) C (= O) ^{R a R a, -N (R} a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) 2 NR ^{selected from a} R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ⁴ is independently in each case H, halo, nitro, cyano, C _1-4 alkyl, OC _1-4 alkyl, OC _1-4 haloalkyl, NHC _1-4 alkyl, N (C _{1-4 alkyl) C 1 to 4 alkyl, C (= O) NH 2} , C (= O) NHC 1~4 _{alkyl, C (= O) N (} C 1~4 _{alkyl) C 1 to 4} alkyl, N (H) C (═O) C _1-4 alkyl, N (C _1-4 alkyl) C (═O) C _1-4 alkyl, C _1-4 haloalkyl, or 0, 1, selected from N, O and S, Unsaturated 5, 6 or 7 membered monocycle containing 2, 3 or 4 atoms, but no more than 1 O or S, halo, C _1-4 alkyl, C _1-3 Haloalkyl, —OC _1-4 alkyl, —NH ₂ , —NHC _1-4 alkyl, — N (C _1-4 alkyl) substituted with 0, 1, 2 or 3 substituents selected from C _1-4 alkyl;
R ⁵ is independently in each case H, halo, nitro, cyano, C _1-4 alkyl, OC _1-4 alkyl, OC _1-4 haloalkyl, NHC _1-4 alkyl, N (C _1-4 Alkyl) C _1-4 alkyl or C _1-4 haloalkyl;
R ⁶ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but no more than 1 O or S, saturated, partially saturated or unsaturated 5 , 6 or 7 membered monocyclic ring or 8, 9, 10 or 11 membered bicyclic ring, wherein available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, Substituted with 0 or 1 R ² substituents, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S ( ═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a independently selected from 0, 1, 2, or 3 substituents Further substituted; or R ⁶ is , H, halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (= O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , — S (= O) ₂ NR ^a R ^a , -S (= O) ₂ N (R ^a ) C (= O) R ^a , -S (= O) ₂ N (R ^a ) C (= O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C ^{(= O) OR a, -N} (R a) C (= ^{) NR a R a, -N (} R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) 2 Selected from NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ⁷ is H, C _1-6 alkyl, —C (═O) N (R ^a ) R ^a , —C (═O) R ^b, or C _1-4 haloalkyl;
R ^a is, in each case independently H or ^{R b;} and R ^b is, in each case, independently, phenyl, benzyl or _C 1 _{~ 6} alkyl, phenyl, benzyl and _{C 1 6} alkyl, _{halo, C 1 to 4 alkyl, C 1 to 3 haloalkyl, -OC 1 to 4 alkyl,} -NH 2, _{-NHC 1 to 4} alkyl, -N _{(C 1 to 4 alkyl) C 1 to 4} Substituted by 0, 1, 2, or 3 substituents selected from alkyl.

In another embodiment, in conjunction with any of the above or below embodiments,
X ² is C (R ⁴ );
X ³ is C (R ⁵ );
X ⁴ is C (R ⁵ ); and X ⁵ is C (R ⁴ ).

In another embodiment, in conjunction with any of the above or below embodiments,
X ² is N;
X ³ is C (R ⁵ );
X ⁴ is C (R ⁵ ); and X ⁵ is C (R ⁴ ).

In another embodiment, in conjunction with any of the above or below embodiments,
X ² is C (R ⁴ );
X ³ is N;
X ⁴ is C (R ⁵ ); and X ⁵ is C (R ⁴ ).

In another embodiment, in conjunction with any of the above or below embodiments,
X ² is C (R ⁴ );
X ³ is C (R ⁵ );
X ⁴ is N; and X ⁵ is C (R ⁴ ).

In another embodiment, in conjunction with any of the above or below embodiments,
X ² is C (R ⁴ );
X ³ is C (R ⁵ );
X ⁴ is C (R ⁵ ); and X ⁵ is N.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ is selected from C _1-6 alkyl and C _1-4 haloalkyl.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or It is a directly bonded unsaturated 5, 6 or 7 membered monocycle or 8, 9, 10 or 11 membered bicycle, containing no more than one S atom, halo, C _1-6 alkyl, C _{1- 4-} haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a _R ^a, _-OC 2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S (= O) 2 R a, -S (= _{^{) 2 NR a R a, -S}} (= O) 2 N (R a) C (= O) R a, -S (= O) 2 N (R a) C (= O) OR a, -S ( ═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a independently selected from 0, Substituted by 1, 2 or 3 substituents, the available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or thioxo groups.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or It is a directly bonded unsaturated 5, 6 or 7 membered monocycle containing no more than one S atom, halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (= O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR substituted with 0, 1, 2 or 3 substituents independently selected from: ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a , The available carbon atoms of the ring are additionally substituted with 0, 1 or 2 oxo or thioxo groups.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ is phenyl or pyridine, any of which are independently of halo, C _1-6 alkyl and C _1-4 haloalkyl. Substituted by 0, 1, 2, or 3 selected substituents.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or A methylene-bonded saturated, partially saturated or unsaturated 5, 6 or 7 membered monocycle or an 8, 9, 10 or 11 membered bicycle, containing no more than one S atom, halo, C _1-6 Alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _{2 6} alkyl _^NR a ^R _{a, -OC} ^2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S ( ═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 Substituted by 0, 1, 2 or 3 substituents independently selected from alkyl OR ^a , the available carbon atoms of said ring are additionally 0, 1 or 2 oxo or thioxo groups Replaced There.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or No more than one S atom, ethylene-bonded saturated, partially saturated or unsaturated 5, 6 or 7 membered monocyclic or 8, 9, 10 or 11 membered bicyclic, halo, C _1-6 Alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _{2 6} alkyl _^NR a ^R _{a, -OC} ^2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S ( ═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 Substituted by 0, 1, 2 or 3 substituents independently selected from alkyl OR ^a , the available carbon atoms of said ring are additionally 0, 1 or 2 oxo or thioxo groups Replaced There.

In another embodiment, in conjunction with any of the above or below embodiments, R ² is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , ^{-C (= O) OR a,} -C (= O) NR a R a, -C (= NR a) NR a R a, -OR a, -OC (= O) R a, -OC (= O ) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , − N (R ^a ) C (= O ) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C Selected from _2-6 alkyl OR ^a .

In another embodiment, in conjunction with any of the above or below embodiments, R ² is selected from halo, C _1-6 alkyl and C _1-4 haloalkyl.

In another embodiment, in conjunction with any of the above or below embodiments, R ² is H.

In another embodiment, in conjunction with any of the above or below embodiments, R ¹ and R ² are taken together to form a halo, cyano, OH, OC _1-4 alkyl, C _1-4 alkyl, C ₁ Substituted with 0, 1, 2 or 3 substituents selected from _˜3 haloalkyl, OC _1-4 alkyl, NH ₂ , NHC _1-4 alkyl and N (C _1-4 alkyl) C _1-4 alkyl Saturated or partially saturated 2, 3, 4 or 5 carbon bridges are formed.

In another embodiment, in conjunction with any of the above or below embodiments, R ³ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or S is selected from saturated, partially saturated or unsaturated 5-, 6- or 7-membered monocycles containing no more than 1 and the available carbon atoms of said ring are 0, 1 or 2 oxo or thioxo Substituted with a group, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O ) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N ( R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 al Kill OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , is further substituted by -NR ^a C _{2 to 6} alkyl ^NR a ^{R a} and ^-NR _{a C} ^2~6 0,1,2 or 3 substituents independently selected from alkyl oR ^a.

In another embodiment, in conjunction with any of the above or below embodiments, R ³ comprises 1, 2, 3 or 4 atoms selected from N, O and S, wherein O or S is Selected from saturated 5, 6 or 7 membered monocycles containing no more than one, wherein available carbon atoms of said ring are substituted by 0, 1 or 2 oxo or thioxo groups, said ring being , Halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (= NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a, _{-OC 2~6} alkyl ^NR _a ^R _{a, -OC} 2~6 alkyl ^OR a, ^-SR a, - _{^{(= O) R a, -S}} (= O) 2 R a, -S (= O) 2 NR a R a, -S (= O) 2 N (R a) C (= O) R a, - S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N ( R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a Further substituted by 0, 1, 2 or 3 substituents independently selected from R ^a and —NR ^a C _2-6 alkyl OR ^a .

In another embodiment, in conjunction with any of the above or below embodiments, R ³ comprises 1, 2, 3 or 4 atoms selected from N, O and S, wherein O or S is Selected from saturated 5, 6 or 7-membered monocycles, containing no more than one, wherein the rings are independently selected from halo, C _1-6 alkyl and C _1-4 haloalkyl Or it is substituted by three substituents.

In another embodiment, in conjunction with any of the above or below embodiments, R ³ comprises 1 or 2 atoms selected from N, O and S, wherein O or S is more than 1 0, 1, 2 or 3 substituents selected from a saturated 6-membered monocyclic ring, wherein the ring is independently selected from halo, C _1-6 alkyl and C _1-4 haloalkyl Is replaced by

In another embodiment, in conjunction with any of the above or below embodiments, R ³ comprises 1 or 2 atoms selected from N, O and S, wherein O or S is more than 1 It is selected from saturated 6-membered monocycles that do not contain much.

In another embodiment, in conjunction with any of the above or below embodiments, R ³ is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , ^{-C (= O) OR a,} -C (= O) NR a R a, -C (= NR a) NR a R a, -OR a, -OC (= O) R a, -OC (= O ) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , − N (R ^a ) C (= O ) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C Selected from _2-6 alkyl OR ^a .

In another embodiment, in conjunction with any of the above or below embodiments, R ⁶ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or S is selected from saturated, partially saturated or unsaturated 5, 6 or 7 membered monocycle or 8, 9, 10 or 11 membered bicycle, which contains no more than one, and the available carbon atoms of said ring are Substituted with 0, 1 or 2 oxo or thioxo groups, the ring is substituted with 0 or 1 R ² substituent, and the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, Cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , — ^{OC (= O) R a,} -OC (= O) NR a R a, -OC (= O _{^{N (R a) S (=}} O) 2 R a, -OC 2~6 alkyl _^NR a ^R _{a, -OC} ^2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S ( ═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 0,1 independently selected from alkyl OR ^a, Or it is further substituted by three substituents.

In another embodiment, in conjunction with any of the above or below embodiments, R ⁶ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but O or S is selected from saturated, partially saturated or unsaturated 5-, 6- or 7-membered monocycles containing no more than 1 and the available carbon atoms of said ring are 0, 1 or 2 oxo or thioxo Substituted with a group, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O ) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N ( R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 al Kill OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , Substituted by 0, 1, 2 or 3 substituents independently selected from —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a .

In another embodiment, in conjunction with any of the above or below embodiments, R ⁶ comprises 1 or 2 atoms selected from N, O and S, wherein O or S is more than 1 Selected from saturated, 5, 6 or 7 membered monocycles, which do not contain much, wherein said rings are independently selected from halo, C _1-6 alkyl and C _1-4 haloalkyl. Substituted by 1 substituent.

In another embodiment, in conjunction with any of the above or below embodiments, R ⁶ is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , ^{-C (= O) OR a,} -C (= O) NR a R a, -C (= NR a) NR a R a, -OR a, -OC (= O) R a, -OC (= O ) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , − N (R ^a ) C (= O ) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C Selected from _2-6 alkyl OR ^a .

In another embodiment, in conjunction with any of the above or below embodiments, R ⁶ is cyano.

  Another aspect of the invention relates to a method for treating a PI3K-mediated condition or disorder.

  In certain embodiments, the PI3K-mediated condition or disorder is selected from rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases. In other embodiments, the PI3K-mediated condition or disorder is cardiovascular disease, atherosclerosis, hypertension, deep vein thrombosis, stroke, myocardial infarction, unstable angina, thromboembolism, pulmonary embolism, thrombus Selected from lytic diseases, acute arterial ischemia, peripheral thrombotic occlusion, and coronary artery disease. In still other embodiments, the PI3K-mediated condition or disorder is cancer, colon cancer, glioblastoma, endometrial cancer, hepatocellular carcinoma, lung cancer, melanoma, renal cell carcinoma, thyroid cancer, cellular lymphoma, lymph Selected from proliferative syndrome, small cell lung cancer, squamous cell lung cancer, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, and leukemia. In yet another embodiment, the PI3K-mediated condition or disorder is selected from type II diabetes. In yet other embodiments, the PI3K-mediated condition or disorder is selected from respiratory disease, bronchitis, asthma, and chronic obstructive pulmonary disease. In certain embodiments, the subject is a human.

  Another aspect of the invention relates to the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases or autoimmune diseases comprising administering a compound according to any of the above embodiments.

  Another aspect of the invention includes the step of administering a compound according to any of the above or below embodiments, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune diseases, inflammation Bowel disorder, inflammatory eye disorder, inflammation or unstable bladder disorder, skin disease with inflammatory component, chronic inflammatory condition, autoimmune disease, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated brain It relates to the treatment of myelitis, idiopathic thrombocytopenic purpura, multiple sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity.

  Another aspect of the invention relates to the treatment of p110δ activity-mediated, dependent or related cancers comprising the step of administering a compound according to any of the above or below embodiments.

  Another aspect of the present invention includes acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative disease, chronic myelogenous leukemia, T cell acute lymphocytic, comprising administering a compound according to any of the above or below embodiments. It relates to the treatment of cancer selected from leukemia, B cell acute lymphocytic leukemia, non-Hodgkin lymphoma, B cell lymphoma, solid tumor and breast cancer.

  Another aspect of the invention relates to a pharmaceutical composition comprising a compound according to any of the above embodiments and a pharmaceutically acceptable diluent or carrier.

  Another aspect of the invention relates to the use of a compound according to any of the above embodiments as a medicament.

  Another aspect of the present invention is the use of a compound according to any of the above embodiments in the manufacture of a medicament for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune diseases About.

  The compounds of the present invention may generally have several asymmetric centers and are typically shown in the form of a racemic mixture. The present invention is intended to encompass racemic mixtures, partially racemic mixtures, individual enantiomers and diastereomers.

  Unless otherwise stated, the following definitions apply to terms in the specification and claims.

"C _Arufa～beta alkyl" branches, refers to an alkyl group containing a cyclic or linear relationship or any combination of the three, carbon atoms minimum α and the maximum value beta, the α and beta represents an integer . The alkyl groups described in this section can also contain one or two double bonds or triple bonds. Examples of C _1-6 alkyl include the following:

が挙げられるが、これらに限定されない。

However, it is not limited to these.

“Benzo group”, alone or in combination, refers to the divalent radical C ₄ H ₄ ═, one representation of which is —CH═CH—CH═CH—, which is a benzene-like ring when in close proximity to another ring. Form, for example, tetrahydronaphthylene, indole and the like.

  The terms “oxo” and “thioxo” represent a ═O group (as in carbonyl) and a ═S group (as in thiocarbonyl), respectively.

  “Halo” or “halogen” means a halogen atom selected from F, Cl, Br and I.

“C _V-W haloalkyl” means an alkyl group as described above wherein any number, at least one hydrogen atom, attached to the alkyl chain is replaced by F, Cl, Br or I.

  “Heterocycle” means a ring containing at least one carbon atom and at least one other atom selected from N, O and S. Examples of heterocycles that can be found in the claims include, but are not limited to:

An “available nitrogen atom” is a nitrogen atom that is part of a heterocycle (eg, piperidine) linked by two single bonds, leaving, for example, an external bond available for substitution with H or CH ₃ .

  "Pharmaceutically acceptable salt" means a salt prepared by conventional means well known to those skilled in the art. “Pharmaceutically acceptable salts” include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid. Acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like include, but are not limited to, salts of inorganic and organic acids. Where the compounds of the present invention contain an acidic functional group such as a carboxy group, suitable pharmaceutically acceptable cation pairs of the carboxy group are well known to those skilled in the art and are alkali, alkaline earth, ammonium, quaternary. Examples include ammonium cations. For additional examples of “pharmaceutically acceptable salts,” see infra and Berge et al. , J. et al. Pharm. Sci. 66: 1 (1977).

  “Saturated, partially saturated or unsaturated” includes saturated substituents of hydrogen, fully unsaturated substituents of hydrogen and partially saturated substituents of hydrogen.

  A “leaving group” generally refers to a group that can be readily substituted with a nucleophilic group such as an amine, thiol, alcohol nucleophilic group or the like. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halide, triflate, tosylate and the like. Preferred leaving groups are indicated herein where appropriate.

  “Protecting group” is generally used in the art to protect selected reactive groups such as carboxy, amino, hydroxy, mercapto and the like from unwanted reactions such as nucleophilicity, electrophilicity, oxidation, reduction, etc. Refers to a well-known group. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenylalkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include benzyl, ortho-methylbenzyl, trityl and benzhydryl, and salts such as phosphonium, ammonium salts, optionally substituted with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl, and the like. However, it is not limited to these. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9- (9-phenylfluorenyl), phenanthrenyl, durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl groups preferably have from 6 to 10 carbon atoms and include, but are not limited to, cyclohexenylmethyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, trifluoroacetyl, trichloroacetyl, phthaloyl, and the like. . A mixture of protecting groups can be used to protect the same amino group. For example, a primary amino group can be protected with both an aralkyl group and an aralkoxycarbonyl group. The amino protecting group can also be combined with the nitrogen to which the amino protecting group is attached to form a heterocyclic ring, such as 1,2-bis (methylene) benzene, phthalimidyl, succinimidyl, maleimidyl, and the like. These heterocyclic groups can further include adjacent aryl and cycloalkyl rings. In addition, the heterocyclic group can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups can be protected against undesired reactions such as oxidation by forming addition salts such as hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups are also suitable for protecting carboxy, hydroxy and mercapto groups. For example, an aralkyl group. Alkyl groups such as tert-butyl are also suitable groups for protecting hydroxy and mercapto groups.

  A silyl protecting group is a silicon atom optionally substituted with one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis (dimethylsilyl) benzene, 1,2-bis (dimethylsilyl) ethane and diphenyl Examples include, but are not limited to, methylsilyl. Silylation of the amino group gives a mono or disilylamino group. When an amino alcohol compound is silylated, an N, N, O-trisilyl derivative can be produced. Removal of the silyl functional group from the silyl ether functional group is treated in situ, for example with a metal hydroxide or ammonium fluoride reagent, or as a separate reaction step or during reaction with an alcohol group. This is easily implemented. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyldimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethylsilyl chloride or a combination product of these with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods for preparing these amine derivatives from the corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in organic chemistry, including amino acid / amino acid ester or amino alcohol chemistry.

  Protecting groups are removed under conditions that do not affect the rest of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. Preferred methods include removal of protecting groups such as removal of the benzyloxycarbonyl group by hydrogenolysis using palladium on carbon in a suitable solvent system such as alcohol, acetic acid, mixtures thereof and the like. The t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid such as HCl or trifluoroacetic acid in a suitable solvent system such as dioxane or methylene chloride. The produced amino salt can be neutralized to easily obtain a free amine. Carboxy protecting groups such as methyl, ethyl, benzyl, tert-butyl, 4-methoxyphenylmethyl can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

  The compounds of the present invention have the following examples:

で示す、環状および非環状のアミジンおよびグアニジン基、ヘテロ原子置換ヘテロアリール基（Ｙ’＝Ｏ、Ｓ、ＮＲ）などの互変異性型として存在し得る基を含み得ることに留意されたく、本明細書において１つの型の名称を挙げ、説明し、表示し、および／または請求しているが、全ての互変異性型が、かかる名称、説明、表示および／または特許請求の範囲に本質的に含まれるものであることに留意されたい。

It should be noted that groups that may exist as tautomeric forms such as cyclic and acyclic amidine and guanidine groups, heteroatom-substituted heteroaryl groups (Y′═O, S, NR), Although the specification lists, describes, indicates and / or claims one type of name, all tautomeric forms are inherent in such names, descriptions, indications and / or claims. Please note that it is included in.

  Prodrugs of the compounds of this invention are also contemplated by this invention. A prodrug is an active or inactive compound that is chemically modified to a compound of the present invention by in vivo physiological actions such as hydrolysis, metabolism, etc. after administration to a patient. The suitability and techniques required for making and using prodrugs are well known to those skilled in the art. For general discussion of prodrugs containing esters, see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of masked carboxylate anions include alkyl (eg, methyl, ethyl), cycloalkyl (eg, cyclohexyl), aralkyl (eg, benzyl, p-methoxybenzyl), alkylcarbonyloxyalkyl (eg, pivalo And various esters such as (Iloxymethyl). Amines are masked as arylcarbonyloxymethyl substituted derivatives. Arylcarbonyloxymethyl substituted derivatives are cleaved in vivo by esterases to release free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). In addition, drugs containing acidic NH groups such as imidazole, imide and indole are masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups are masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich base hydroxamic acid prodrugs, their preparation and use.

  The specification and claims include a series of species that use the expression "selected from ... and ..." and "is ... or ..." (sometimes referred to as a Markush group). As used in this application, this expression shall include the entire group, any single component thereof, or any subgroup thereof, unless otherwise specified. The use of this term is merely for shorthand purposes and in no way limits the exclusion of individual elements or subgroups as necessary.

Use the following abbreviations:
aq. - aqueous solution BINAP- 2,2'-bis (diphenylphosphino) 1,1'-binaphthyl concd- concentrated DCM- dichloromethane DMF -N, N-dimethylformamide DMSO- dimethylsulphoxide _Et 2 O-diethyl ether EtOAc- acetate Ethyl EtOH- Ethyl alcohol h- Time min- Minute MeOH- Methyl alcohol NMP- 1-Methyl-2-pyrrolidinone rt- Room temperature satd- Saturated TFA- Trifluoroacetic acid THF- Tetrahydrofuran X-Phos-2-dicyclohexylphosphino-2 ' , 4 ′, 6′-Tri-isopropyl-1,1′-biphenyl

Summary The reagents and solvents used below can be obtained from commercial sources. ¹ H-NMR spectra were recorded on a Bruker 400 MHz and 500 MHz NMR spectrometer. The notable peaks are summarized in the following order: proton number, multiplicity (s, singlet; d, doublet; t, triplet; q, quadruple; m, multiplet; brs, broad singlet ), And hertz (Hz) coupling constant (s). Mass spectrometry results are reported as the ratio of mass to charge followed by the relative abundance of each ion (parentheses). Electrospray ionization (ESI) mass spectrometry was performed on an Agilent 1100 series LC / MSD electrospray mass spectrometer.

All compounds could be analyzed in positive ESI mode using acetonitrile: water with 0.1% formic acid as delivery solvent. Reverse phase analytical HPLC was performed using an Agilent 1200 series Agilent Eclipse XDB-C18 5 μm column (4.6 × 150 mm) as the stationary phase, eluting with 0.1% TFA in acetonitrile: H ₂ O. Semi-preparative reverse phase HPLC was performed using an Agilent 1100 series Phenomenex Gemini® 10 μm C18 column (250 × 21.20 mm) eluting with 0.1% TFA in acetonitrile: H ₂ O.

  Method A

置換アニリン（１等量）のピリジン（２等量）中の混合物をマロン酸ジエチルアルキル（１．５等量）で処理し、撹拌した混合物を１３０℃で２４時間加熱した。その後、反応物をマロン酸ジエチルアキル（０．５等量）で処理し、１３０℃でさらに１２時間加熱した。その後、反応物を室温に冷却して、減圧蒸発させた。粗生成物をＤＣＭ中に取り込み、飽和重炭酸ナトリウム水溶液で洗浄して、分離した有機層を硫酸マグネシウム上で乾燥させ、濾過し、減圧蒸発させた。粗生成物をベンゼンに溶解し、減圧蒸発させた。粗生成物をカラムクロマトグラフィーによりシリカ上で精製し（ヘキサン：ＥｔＯＡｃ、１：０〜３：１勾配を溶離剤として使用）、エチル置換フェニルアミノ−オキソプロパノエートを得た。

A mixture of substituted aniline (1 equivalent) in pyridine (2 equivalents) was treated with diethyl alkyl malonate (1.5 equivalents) and the stirred mixture was heated at 130 ° C. for 24 hours. The reaction was then treated with diethylalkyl malonate (0.5 equivalent) and heated at 130 ° C. for an additional 12 hours. The reaction was then cooled to room temperature and evaporated under reduced pressure. The crude product was taken up in DCM and washed with saturated aqueous sodium bicarbonate, and the separated organic layer was dried over magnesium sulfate, filtered and evaporated under reduced pressure. The crude product was dissolved in benzene and evaporated under reduced pressure. The crude product was purified on silica by column chromatography (hexane: EtOAc, 1: 0 to 3: 1 gradient as eluent) to give ethyl substituted phenylamino-oxopropanoate.

  Method B

エチル置換フェニルアミノ−オキソプロパノエート（１等量）のＴＨＦ、水（ＴＨＦ：水４：１、０．８７８Ｍ）中の混合物を水酸化ナトリウム（１．２等量）で処理して、室温で１時間撹拌した。その後、反応物を濃ＨＣｌでｐＨ２に酸性化してから、ＥｔＯＡｃで抽出した。分離した有機層を硫酸マグネシウム上で乾燥させ、濾過し、減圧蒸発させて、置換フェニルアミノ−オキソプロパン酸を得た。

A mixture of ethyl substituted phenylamino-oxopropanoate (1 equivalent) in THF, water (THF: water 4: 1, 0.878M) was treated with sodium hydroxide (1.2 equivalents) at room temperature. For 1 hour. The reaction was then acidified to pH 2 with conc. HCl and extracted with EtOAc. The separated organic layer was dried over magnesium sulfate, filtered and evaporated under reduced pressure to give substituted phenylamino-oxopropanoic acid.

  Method C

フェニルアミノ−オキソプロパン酸のポリリン酸溶液（０．６Ｍ）中の混合物を１３０℃で２時間撹拌した。その後、反応物を室温に冷却して、沈殿物が形成されるまで２Ｍ水酸化ナトリウム水溶液で処理した。沈殿物を濾過し、１Ｍ水酸化ナトリウム水溶液で洗浄して、真空乾燥させて、置換キノリンジオールを得た。

A mixture of phenylamino-oxopropanoic acid in polyphosphoric acid solution (0.6 M) was stirred at 130 ° C. for 2 hours. The reaction was then cooled to room temperature and treated with 2M aqueous sodium hydroxide until a precipitate formed. The precipitate was filtered, washed with 1M aqueous sodium hydroxide solution and dried in vacuo to give a substituted quinolinediol.

  Method D

キノリンジオール（１等量）およびオキシ塩化リン（１０等量）の混合物を１００℃で２時間加熱した。その後、反応物を室温に冷却して、減圧蒸発させた。生成した褐色残基をＤＣＭ中に取り込み、水で洗浄した。分離した有機層を硫酸マグネシウム上で乾燥させ、濾過し、減圧蒸発させた。次いで、生成物をカラムクロマトグラフィーにより精製し（ヘキサンおよびＥｔＯＡｃの９対１混合物を溶離剤として使用）、置換ジクロロキノリンを得た。

A mixture of quinolinediol (1 equivalent) and phosphorus oxychloride (10 equivalents) was heated at 100 ° C. for 2 hours. The reaction was then cooled to room temperature and evaporated under reduced pressure. The resulting brown residue was taken up in DCM and washed with water. The separated organic layer was dried over magnesium sulfate, filtered and evaporated under reduced pressure. The product was then purified by column chromatography (using a 9: 1 mixture of hexane and EtOAc as eluent) to give the substituted dichloroquinoline.

  Method E

置換ジクロロキノリン（１等量）、スチル試薬（１等量）およびテトラキス（トリフェニルホスフィン）パラジウム（０．１等量）のトルエン（０．２１Ｍ）中の混合物を還流で一晩加熱した。その後、反応物を室温に冷却して、ＥｔＯＡｃおよび水で処理した。分離した有機層を硫酸マグネシウム上で乾燥させ、濾過し、真空蒸発させた。カラムクロマトグラフィーにより、置換４−クロロキノリンを得た。

A mixture of substituted dichloroquinoline (1 equivalent), stil reagent (1 equivalent) and tetrakis (triphenylphosphine) palladium (0.1 equivalent) in toluene (0.21 M) was heated at reflux overnight. The reaction was then cooled to room temperature and treated with EtOAc and water. The separated organic layer was dried over magnesium sulfate, filtered and evaporated in vacuo. Substituted 4-chloroquinoline was obtained by column chromatography.

  Method F

置換ジクロロキノリン（１等量）、ボロン酸（１等量）、炭酸ナトリウム（２等量）およびテトラキス（トリフェニルホスフィン）パラジウム（０．１等量）のトルエン、水（トルエン：水５：２、０．１５Ｍ）中の混合物を還流で一晩加熱した。その後、反応物を室温に冷却して、ＥｔＯＡｃおよび水で処理した。分離した有機層を硫酸マグネシウム上で乾燥させ、濾過し、真空蒸発させた。カラムクロマトグラフィーにより、置換４−クロロキノリンを得た。

Substituted dichloroquinoline (1 equivalent), boronic acid (1 equivalent), sodium carbonate (2 equivalents) and tetrakis (triphenylphosphine) palladium (0.1 equivalent) in toluene, water (toluene: water 5: 2) , 0.15M) was heated at reflux overnight. The reaction was then cooled to room temperature and treated with EtOAc and water. The separated organic layer was dried over magnesium sulfate, filtered and evaporated in vacuo. Substituted 4-chloroquinoline was obtained by column chromatography.

  Method G

置換ジクロロキノリン（１等量）およびアミン（Ｒ_３−Ｈ、１等量）のイソプロパノール（０．４Ｍ）中の混合物を密封試験管内で８５℃で一晩加熱した。反応物を室温に冷却して、減圧下濃縮、乾燥させた。次いで、残基を中圧クロマトグラフィーにより精製し、対応する置換４−クロロキノリンを得た。

A mixture of substituted dichloroquinoline (1 equivalent) and amine (R ₃ —H, 1 equivalent) in isopropanol (0.4 M) was heated in a sealed tube at 85 ° C. overnight. The reaction was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was then purified by medium pressure chromatography to give the corresponding substituted 4-chloroquinoline.

  Method H

置換４−クロロキノリンまたは４−ブロモキノリン（１等量）およびアミン（Ｒ_４−Ｈ、１．１等量）、ナトリウムｔｅｒｔ−ブトキシド（２．５等量）、Ｘ−Ｐｈｏｓ（０．１６等量）およびトリス（ジベンジリデンアセトン）ジパラジウム（０）（０．０４等量）の適切な溶媒（０．５Ｍ）中の混合物を油浴またはマイクロ波反応装置で１１０℃で４５分間加熱した。反応物を室温に冷却して、水で希釈した。混合物をＥｔＯＡｃ、ＤＣＭまたは１０％ＭｅＯＨ：ＤＣＭ混合物で抽出した。合わせた有機層を硫酸マグネシウム上で乾燥させて、濾過した。ろ液を減圧濃縮してから、残基を中圧クロマトグラフィーにより精製し、対応する置換キノリンを得た。

Substituted 4-chloroquinoline or 4-bromo-quinoline (1 eq) and an amine _(R 4 -H, 1.1 eq), sodium tert- butoxide (2.5 eq), X-Phos (0.16, etc. Amount) and tris (dibenzylideneacetone) dipalladium (0) (0.04 equivalents) in a suitable solvent (0.5M) were heated in an oil bath or microwave reactor at 110 ° C. for 45 minutes. The reaction was cooled to room temperature and diluted with water. The mixture was extracted with EtOAc, DCM or 10% MeOH: DCM mixture. The combined organic layers were dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by medium pressure chromatography to give the corresponding substituted quinoline.

  Method I

置換４−クロロキノリンまたは４−ブロモキノリン（１等量）、他の窒素含有試薬（Ｒ_３−Ｈ、１．１等量）、炭酸カリウム（２．５等量）、ジ−ｔｅｒｔ−ブチル（２’，４’，６’−トリイソプロピル−３，４，５，６−テトラメチルビフェニル−２−イル）ホスフィン（０．０５等量）、活性化３オングストローム分子篩およびトリス（ジベンジルイデネアセトン）ジパラジウム（０）（０．０２等量）の適切な溶媒（０．５Ｍ）中の混合物を油浴またはマイクロ波反応装置で１１０℃で３時間加熱した。反応物を室温に冷却して、濾過した。ろ液に水を添加して、混合物をＥｔＯＡｃ、ＤＣＭまたは１０％ＭｅＯＨ：ＤＣＭ混合物で抽出した。合わせた有機層を硫酸マグネシウム上で乾燥させて、濾過した。ろ液を減圧濃縮してから、残基を中圧クロマトグラフィーにより精製し、対応する置換キノリンを得た。

Substituted 4-chloroquinoline or 4-bromo-quinoline (1 eq), other nitrogen-containing reagents _(R 3 -H, 1.1 eq), potassium carbonate (2.5 eq), di -tert- butyl ( 2 ', 4', 6'-triisopropyl-3,4,5,6-tetramethylbiphenyl-2-yl) phosphine (0.05 equivalent), activated 3 angstrom molecular sieve and tris (dibenzylideneacetone ) A mixture of dipalladium (0) (0.02 equivalents) in a suitable solvent (0.5M) was heated in an oil bath or microwave reactor at 110 ° C. for 3 hours. The reaction was cooled to room temperature and filtered. Water was added to the filtrate and the mixture was extracted with EtOAc, DCM or 10% MeOH: DCM mixture. The combined organic layers were dried over magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by medium pressure chromatography to give the corresponding substituted quinoline.

  Method J

アミノ安息香酸（１．３等量）およびアリールプロパノン（１．０等量）のオキシ塩化リン（０．５Ｍ）中の混合物を９０℃に２時間加熱してから、減圧濃縮した。濃縮物をＤＣＭと飽和重炭酸ナトリウム水溶液間に分配して、１時間激しく撹拌した。有機抽出物を水、次いでブラインで洗浄し、無水硫酸マグネシウム上で撹拌し、濾過し、ろ液を減圧濃縮した。生成物をカラムクロマトグラフィーによりシリカゲル上で単離し、ヘキサン中ＥｔＯＡｃ勾配で溶出した。

A mixture of aminobenzoic acid (1.3 eq) and arylpropanone (1.0 eq) in phosphorus oxychloride (0.5 M) was heated to 90 ° C. for 2 hours and then concentrated under reduced pressure. The concentrate was partitioned between DCM and saturated aqueous sodium bicarbonate and stirred vigorously for 1 hour. The organic extract was washed with water then brine, stirred over anhydrous magnesium sulfate, filtered and the filtrate concentrated in vacuo. The product was isolated on silica gel by column chromatography and eluted with an EtOAc gradient in hexane.

  Method K

方法１：
置換キノリン（１．０等量）、置換アニリン（１．０等量）および１，４−ジオキサン（１．０等量）中の４．０Ｎ塩酸溶液の、ＭｅＯＨ（０．４Ｍ）中の混合物をマイクロ波で１５０℃で２時間加熱した。反応物をＤＣＭと飽和重炭酸ナトリウム水溶液間に分配した。有機分離物を無水硫酸マグネシウム上で撹拌し、濾過し、ろ液を減圧濃縮して生成物を得、これをカラムクロマトグラフィーによりシリカゲル上で単離した。
方法２：
置換キノリン（２．０等量）、置換アニリン（１．０等量）および１，４−ジオキサン（０．１等量）中の４Ｎ塩酸の、１−メチル−２−ピロリジノン溶液（０．８Ｍ）中の混合物をマイクロ波で１５０℃で４時間加熱した。反応物をＥｔＯＡｃと飽和重炭酸ナトリウム水溶液間に分配した。有機分離物を水、次いでブラインで洗浄し、無水硫酸マグネシウム上で撹拌し、濾過し、ろ液を減圧濃縮して生成物を得、これをクロマトグラフィーによりシリカゲル上で単離した。

Method 1:
A mixture of 4.0 N hydrochloric acid solution in substituted quinoline (1.0 equivalent), substituted aniline (1.0 equivalent) and 1,4-dioxane (1.0 equivalent) in MeOH (0.4 M). Was heated in the microwave at 150 ° C. for 2 hours. The reaction was partitioned between DCM and saturated aqueous sodium bicarbonate. The organic separation was stirred over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated in vacuo to give the product, which was isolated on silica gel by column chromatography.
Method 2:
1-methyl-2-pyrrolidinone solution (0.8 M) of 4N hydrochloric acid in substituted quinoline (2.0 eq), substituted aniline (1.0 eq) and 1,4-dioxane (0.1 eq) ) Was heated in the microwave at 150 ° C. for 4 hours. The reaction was partitioned between EtOAc and saturated aqueous sodium bicarbonate. The organic separation was washed with water then brine, stirred over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated in vacuo to give the product, which was isolated by chromatography on silica gel.

[Example 1]
Preparation of N- (7-fluoro-3-methyl-2- (pyridin-2-yl) quinolin-4-yl) 5-morpholino-1,2,4-thiadiazol-3-amine 7-Fluoro-N- ( 4-Methoxybenzyl) 3-methyl-2- (pyridin-2-yl) quinolin-4-amine

２−（ジシクロヘキシルホスフィノ）−２’，４’，６’−トリイソプロピル−ビフェニル（１７５ｍｇ、０．３７ｍｍｏｌ）、トリス（ジベンジリデンアセトン）ジパラジウム（０）（１６８ｍｇ、０．１８３ｍｍｏｌ）、４−クロロ−７−フルオロ−３−メチル−２−（ピリジン−２−イル）キノリン（０．５０ｇ、１．８３ｍｍｏｌ）および４−メトキシベンジルアミン（２３８μＬ、１．８３ｍｍｏｌ）の撹拌したトルエン（６１１２μＬ、１．８３ｍｍｏｌ）中の溶液にナトリウムｔｅｒｔ−ブトキシド（３５２ｍｇ、３．６７ｍｍｏｌ）を添加した。反応混合物を１００℃に加熱して、３０分間撹拌した。その後、粗反応混合物をアルミナプラグを介して濾過し、酢酸エチルで溶出して、ろ液を真空濃縮した。粗生成物をカラムクロマトグラフィーによりアルミナ上で精製し（ヘキサン中０〜５０％酢酸エチル）、所望の生成物７−フルオロ−Ｎ−（４−メトキシベンジル）−３−メチル−２−（ピリジン−２−イル）キノリン−４−アミンを得た。質量スペクトル（ＥＳＩ）ｍ／ｅ＝３７４．１（Ｍ＋１）。

2- (dicyclohexylphosphino) -2 ′, 4 ′, 6′-triisopropyl-biphenyl (175 mg, 0.37 mmol), tris (dibenzylideneacetone) dipalladium (0) (168 mg, 0.183 mmol), 4- Chloro-7-fluoro-3-methyl-2- (pyridin-2-yl) quinoline (0.50 g, 1.83 mmol) and 4-methoxybenzylamine (238 μL, 1.83 mmol) in stirred toluene (6112 μL, 1 Sodium tert-butoxide (352 mg, 3.67 mmol) was added to the solution in .83 mmol). The reaction mixture was heated to 100 ° C. and stirred for 30 minutes. The crude reaction mixture was then filtered through an alumina plug, eluted with ethyl acetate, and the filtrate was concentrated in vacuo. The crude product was purified on alumina by column chromatography (0-50% ethyl acetate in hexane) to give the desired product 7-fluoro-N- (4-methoxybenzyl) -3-methyl-2- (pyridine- 2-yl) quinolin-4-amine was obtained. Mass spectrum (ESI) m / e = 374.1 (M + l).

  7-Fluoro-3-methyl-2- (pyridin-2-yl) quinolin-4-amine

７−フルオロ−Ｎ−（４−メトキシベンジル）−３−メチル−２−（ピリジン−２−イル）キノリン−４−アミン（０．４８６ｇ、１．３０ｍｍｏｌ）の撹拌したジクロロメタン（１３．０ｍＬ）中の溶液にＴＦＡ（０．５ｍＬ、６．４９ｍｍｏｌ）を添加した。撹拌を２３℃で２６時間継続した。その後、反応物を真空濃縮し、酢酸エチルに溶解させ、飽和重炭酸ナトリウム溶液で洗浄した。合わせた有機層を真空濃縮して、シリカゲル上で精製し、０〜１０％メタノールのジクロロメタン溶液で溶出し、所望の生成物７−フルオロ−３−メチル−２−（ピリジン−２−イル）キノリン−４−アミンを得た。質量スペクトル（ＥＳＩ）ｍ／ｅ＝２５４．１（Ｍ＋１）。

7-Fluoro-N- (4-methoxybenzyl) -3-methyl-2- (pyridin-2-yl) quinolin-4-amine (0.486 g, 1.30 mmol) in stirred dichloromethane (13.0 mL). To the solution was added TFA (0.5 mL, 6.49 mmol). Stirring was continued at 23 ° C. for 26 hours. The reaction was then concentrated in vacuo, dissolved in ethyl acetate and washed with saturated sodium bicarbonate solution. The combined organic layers were concentrated in vacuo and purified on silica gel, eluting with 0-10% methanol in dichloromethane to give the desired product 7-fluoro-3-methyl-2- (pyridin-2-yl) quinoline. -4-Amine was obtained. Mass spectrum (ESI) m / e = 254.1 (M + l).

  N- (7-Fluoro-3-methyl-2- (pyridin-2-yl) quinolin-4-yl) -5-morpholino-1,2,4-thiadiazol-3-amine

ジシクロヘキシル（２’，４’，６’−トリイソプロピルビフェニル−２−イル）ホスフィン（０．０１８ｇ、０．０３８ｍｍｏｌ）、４−（３−ブロモ−１，２，４−チアジアゾール−５−イル）モルフォリン（０．０５９ｇ、０．２４ｍｍｏｌ）、７−フルオロ−３−メチル−２−（ピリジン−２−イル）キノリン−４−アミン（０．０６ｇ、０．２４ｍｍｏｌ）およびＰｄ_２ｄｂａ_３（０．００９ｇ、９．４８μｍｏｌ）の撹拌したトルエン（２．４ｍＬ）中の溶液にナトリウムｔｅｒｔ−ブトキシド（０．０５７ｇ、０．５９２ｍｍｏｌ）を添加した。反応混合物を１００℃に加熱して、１時間撹拌した。粗反応混合物をアルミナプラグを介して濾過し、（ジクロロメタン／メタノール；３／１）で溶出し、ろ液を濃縮真空した。粗生成物をカラムクロマトグラフィーによりアルミナ上で精製し（０〜６０％酢酸エチル／ヘキサン）、所望の生成物を得た。所望の生成物をさらにＨＰＬＣで精製した（０．１％ＴＦＡ水溶液中０．１％ＴＦＡアセトニトリル溶液１０〜９０％）。所望の画分を濃縮してから、酢酸エチルで希釈した。飽和重炭酸ナトリウム水溶液で２回洗浄後、溶媒を減圧除去して、純粋な生成物Ｎ−（７−フルオロ−３−メチル−２−（ピリジン−２−イル）キノリン−４−イル）−５−モルホリノ−１，２，４−チアジアゾール−３−アミンを得た。１Ｈ ＮＭＲ（４００ＭＨｚ、ＣＤ_２Ｃｌ_２）δ ｐｐｍ８．６５（１Ｈ、ｄ、Ｊ＝３．９Ｈｚ）、８．０３（１Ｈ、ｄｄ、Ｊ＝９．２、５．９Ｈｚ）、７．９４（１Ｈ、ｔｄ、Ｊ＝７．７、１．８Ｈｚ）、７．７４（１Ｈ、ｄ、Ｊ＝７．８Ｈｚ）、７．６７（１Ｈ、ｄｄ、Ｊ＝１０．０、２．７Ｈｚ）、７．３９〜７．４９（１Ｈ、ｍ）、７．３２（１Ｈ、ｄｄｄ、Ｊ＝９．３、８．２、２．４Ｈｚ）、３．７１〜３．８３（４Ｈ、ｍ）、３．３７〜３．５０（４Ｈ、ｍ）、２．２８（３Ｈ、ｓ）。質量スペクトル（ＥＳＩ）ｍ／ｅ＝４２３．２（Ｍ＋１）。

Dicyclohexyl (2 ′, 4 ′, 6′-triisopropylbiphenyl-2-yl) phosphine (0.018 g, 0.038 mmol), 4- (3-bromo-1,2,4-thiadiazol-5-yl) morpho Phosphorus (0.059 g, 0.24 mmol), 7-fluoro-3-methyl-2- (pyridin-2-yl) quinolin-4-amine (0.06 g, 0.24 mmol) and Pd ₂ dba ₃ (0. To a solution of 009 g, 9.48 μmol) in stirred toluene (2.4 mL) was added sodium tert-butoxide (0.057 g, 0.592 mmol). The reaction mixture was heated to 100 ° C. and stirred for 1 hour. The crude reaction mixture was filtered through an alumina plug, eluting with (dichloromethane / methanol; 3/1) and the filtrate was concentrated in vacuo. The crude product was purified on alumina by column chromatography (0-60% ethyl acetate / hexane) to give the desired product. The desired product was further purified by HPLC (10% to 90% 0.1% TFA acetonitrile solution in 0.1% aqueous TFA). The desired fraction was concentrated and then diluted with ethyl acetate. After washing twice with saturated aqueous sodium bicarbonate solution, the solvent was removed under reduced pressure to give pure product N- (7-fluoro-3-methyl-2- (pyridin-2-yl) quinolin-4-yl) -5. -Morpholino-1,2,4-thiadiazol-3-amine was obtained. 1H NMR (400 MHz, CD ₂ Cl ₂ ) δ ppm 8.65 (1H, d, J = 3.9 Hz), 8.03 (1H, dd, J = 9.2, 5.9 Hz), 7.94 (1H , Td, J = 7.7, 1.8 Hz), 7.74 (1H, d, J = 7.8 Hz), 7.67 (1H, dd, J = 10.0, 2.7 Hz), 7. 39-7.49 (1H, m), 7.32 (1H, ddd, J = 9.3, 8.2, 2.4 Hz), 3.71-3.83 (4H, m), 3.37 ~ 3.50 (4H, m), 2.28 (3H, s). Mass spectrum (ESI) m / e = 423.2 (M + l).

Biological Assays Recombinant Expression of PI3K PI3kα, β and δ full-length p110 subunits N-terminally labeled with a polyhistidine tag were coexpressed with p85 in sf9 insect cells using baculovirus expression vectors. P110 / p85 heterodimer was purified by sequential Ni-NTA, Q-HP, Superdex-100 chromatography. Purified α, β and δ isozymes were stored at −20 ° C. in 20 mM Tris, pH 8, 0.2 M NaCl, 50% glycerol, 5 mM DTT, 2 mM sodium cholate. N-terminal truncated PI3Kγ labeled with a polyhistidine tag, residues 114 to 1102 were expressed in ba5 virus in Hi5 insect cells. The gamma isozyme was purified by sequential Ni-NTA, Superdex-200, Q-HP chromatography. The γ isozyme was stored frozen at −80 ° C. in NaH ₂ PO ₄ , pH ₈ , 0.2 M NaCl, 1% ethylene glycol, 2 mM β-mercaptoethanol.

In Vitro PI3K Enzyme Assay The PI3K alphascreen ™ assay (PerkinElmer, Waltham, Mass.) Was used to measure the activity of a panel of four phosphoinositide 3-kinases, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ. Enzyme reaction buffer was prepared using sterile water (Baxter, Deerfield, IL) and 50 mM Tris HCl pH ₇ , 14 mM MgCl ₂ , 2 mM sodium cholate, and 100 mM NaCl. 2 mM new DTT was added on the day of the experiment. Alpha screen buffer was made using sterile water and 10 mM Tris HCl pH 7.5, 150 mM NaCl, 0.10% Tween 20, and 30 mM EDTA. On the day of the experiment, 1 mM new DTT was added. The compound source plate used for this assay was a 384 well Greiner clear polypropylene plate containing test compounds diluted 1: 2 over 5 mM and 22 concentrations. Since columns 23 and 24 contained positive and negative controls, respectively, these wells contained only DMSO. The original plate was replicated by transferring 0.5 μL / well into 384 well Optiplates (PerkinElmer, Waltham, Mass.).

Each PI3K isoform was diluted 2 fold into working stock with enzyme reaction buffer. PI3Kα was diluted to 1.6 nM, PI3Kβ was diluted to 0.8 nM, PI3Kγ was diluted to 15 nM, and PI3Kδ was diluted to 1.6 nM. PI (4,5) P2 (Echelon Biosciences, Salt Lake City, UT) was diluted to 10 μM and ATP was diluted to 20 μM. This 2-fold stock was used for PI3Kα and PI3Kβ assays. Similar PI stocks were prepared for PI3Kγ and PI3Kδ assays by diluting PI (4,5) P2 to 10 μM and ATP to 8 μM. Alpha screen reaction solutions were made using beads from an anti-GST alpha screen kit (PerkinElmer, Waltham, Mass.). Two 4 × working stocks of alpha screen reagent were made in alpha screen reaction buffer. In the first stock, biotinylated IP ₄ (Echelon Biosciences, Salt Lake City, UT) was diluted to 40 nM and streptavidin-donor beads were diluted to 80 μg / mL. In the second stock was diluted PIP ₃ binding protein (Echelon Biosciences, Salt Lake City, UT) to 40 nM, diluted anti-GST- acceptor beads 80 [mu] g / mL. As a negative control, a reference inhibitor at a concentration >> Ki (40 μM) was included in column 24 as a negative (100% inhibition) control.

  Using a 384 well branch (Titertek, Huntsville, AL), 10 μL / well of 2 × enzyme stock for each isoform was added to columns 1-24 of the assay plate. 10 μL / well of appropriate substrate 2-fold stock (containing 20 μM ATP for PI3Kα and β assays and 8 μM ATP for PI3Kγ and δ assays) was then added to columns 1-24 of all plates. The plate was then incubated for 20 minutes at room temperature. In the dark, 10 μL / well of donor bead solution was added to columns 1-24 of the plate to quench the enzyme reaction. Plates were incubated for 30 minutes at room temperature. Still in the dark, 10 μL / well of acceptor bead solution was added to columns 1-24 of the plate. The plate was then incubated for 1.5 hours in the dark. Plates were read on an Envision multimode plate reader (PerkinElmer, Waltham, Mass.) Using a 680 nm excitation filter and a 520-620 nm emission filter.

Alternative in vitro enzyme assay.
The assay was performed in white polypropylene plates (Costar 3355) in 25 μL containing the final concentration of components. The phosphatidylinositol phosphoacceptor, PtdIns (4,5) P2 P4508, was from Echelon Biosciences. The ATPase activity of α and γ isozymes was not greatly stimulated by PtdIns (4,5) P2 under these conditions and was omitted from these isozyme assays. The test compound was dissolved in dimethyl sulfoxide and diluted by 3-fold serial dilution. Compounds in DMSO (1 μL) were added to each test well and inhibition compared to reactions without compound was determined with and without enzyme. After incubation of the assay at room temperature, the reaction was stopped and residual ATP was determined by adding an equal amount of a commercial ATP bioluminescence kit (Perkin Elmer EasyLite) according to the manufacturer's instructions and using an Analyst GT luminometer And detected.

Stimulation of human B cell proliferation by anti-IgM Isolation of human B cells:
Isolate PBMC from Leukopac or from fresh human blood. Isolate human B cells using the Milteny protocol and B cell isolation kit II. Human B cells were purified using an AutoMacs® column.
Human B Cell Activation Purified B cells in B cell growth medium (DMEM + 5% FCS, 10 mM Hepes, 50 μM 2-mercaptoethanol) are cultured at 50000 / well using 96 well flat bottom plates; 150 μL medium is 250 ng / mL Contains CD40L-LZ recombinant protein (Amgen) and 2 μg / mL anti-human IgM antibody (Jackson ImmunoResearch Lab. # 109-006-129), mixed with 50 μL B cell medium containing PI3K inhibitor at 37 ° C. in an incubator Incubate for 72 hours. After 72 hours, B cells are pulse labeled with 0.5-1 uCi / well ³ H thymidine overnight to 18 hours and cells are harvested using a TOM harvester.

Stimulation of human B cell proliferation by IL-4:
Isolation of human B cells:
Isolate human PBMC from Leukopac or from fresh human blood. Isolate human B cells using the Milteny protocol-B cell isolation kit. Human B cells were purified with an AutoMacs column.
Activation of human B cells Purified B cells in B cell growth medium (DMEM + 5% FCS, 50 μM 2-mercaptoethanol, 10 mM Hepes) are cultured at 50000 / well using 96 well flat bottom plates; medium (150 μL) is 250 ng / mL CD40L-LZ recombinant protein (Amgen) and 10 ng / mL IL-4 (R & D system # 204-IL-025), compounded with 50 150 μL B cell medium containing compound and 72 in 37 ° C. in an incubator. Incubate for hours. After 72 hours, B cells are pulse labeled with 0.5-1 uCi / well 3H thymidine overnight for approximately 18 hours, and cells are harvested using a TOM harvester.

Specific T Antigen (Tetanus Toxin) Induced Human PBMC Proliferation Assay Human PBMC are prepared from frozen stocks or they are purified from fresh human blood using a Ficoll gradient. Incubate with 2 × 10 ⁵ PBMC / well with culture medium (RPMI1640 + 10% FCS, 50 μM 2-mercaptoethanol, 10 mM Hepes) using 96 well round bottom plates. For IC ₅₀ determinations, PI3K inhibitors were tested in triplicate at half log increments from 10 μM to 0.001 μM. Tetanus toxin, T cell specific antigen (University of Massachusetts Lab) was added at 1 μg / mL and incubated at 37 ° C. for 6 days in an incubator. Supernatants are collected after 6 days for IL2 ELISA assay, and then cells are pulsed with ³ H-thymidine for about 18 hours to measure proliferation.

GFP Assay for Detection of Class Ia and Class III PI3K Inhibition AKT1 (PKBa) is regulated by PI3K activation of class Ia activated by mitogenic factors (IGF-1, PDGF, insulin, thrombin, NGF, etc.) The In response to mitogen stimulation, AKT1 moves from the cytosol to the plasma membrane.
Forkhead (FKHRL1) is a substrate for AKT1. It is cytoplasmic when phosphorylated by AKT (survival / proliferation). Inhibition of AKT (congestion / apoptosis) results in translocation of the forkhead to the nucleus.
The FYVE domain binds to PI (3) P. Most are generated by constitutive activation of PI3K class III

AKT film wavy phenomenon assay (CHO-IR-AKT1-EGFP cells / GE Healthcare)
Wash cells with assay buffer. Compounds are treated for 1 hour in assay buffer. Add 10 ng / mL insulin. After 10 minutes, fix at room temperature and image.

Forkhead migration assay (MDA MB468 Forkhead DiversGFP cells)
Cells are treated with compounds in growth medium for 1 hour. Fix and contrast.

Class III PI (3) P assay (U2OS EGFP-2XFYVE cells / GE Healthcare)
Wash cells with assay buffer. Treat compounds with assay buffer for 1 hour. Fix and contrast.
The control for all three assays is 10 μM wortmannin:
AKT is cytoplasmic Forkhead is nuclear PI (3) P is depleted from endosomes

Bioindicator assay: B cell receptor stimulation of CD69 or B7.2 (CD86) expression Heparinized human whole blood was stimulated with 10 μg / mL anti-IgD (Southern Biotech, # 9030-01). Next, 90 μL of stimulated blood was aliquoted into each well of a 96-well plate and treated with 10 μL of various concentrations of blocking compound (10-0.0003 μM) diluted in IMDM + 10% FBS (Gibco). Both samples were incubated at 37 ° C. for 4 hours (for CD69 expression) to 6 hours (for B7.2 expression). The treated blood (50 μL) was combined with 10 μL each of CD45-PerCP (BD Biosciences, # 347464), CD19-FITC (BD Biosciences, # 340719), and CD69-PE (BD Biosciences, # 341652) in 96 wells for antibody staining. And transferred to a deep well plate (Nunc). 50 μL of the second treated blood was transferred to a second 96 well, deep well plate for antibody staining with 10 μL each of CD19-FITC (BD Biosciences, # 340719) and CD86-PeCy5 (BD Biosciences, # 555666). . All staining solutions were performed in the dark at room temperature for 15-30 minutes. The blood was then lysed and fixed for 15 minutes at room temperature using 450 μL FACS lysate (BD Biosciences, # 349202). Samples were then washed twice with PBS + 2% FBS before FACS analysis. Samples were induced on either CD45 / CD19 double positive cells for CD69 staining or CD19 positive cells for CD86 staining.

Gamma counterscreen: human monocyte stimulation for phosphorylated AKT expression The human monocyte cell line, THP-1, was maintained in RPMI + 10% FBS (Gibco). The day before stimulation, cells were counted on a hemocytometer using trypan blue exclusion and suspended at 1 × 10 ⁶ cells / mL media concentration. Then 100 μL cells + medium (1 × 10 ⁵ cells) were aliquoted into each well of a 4-96 well, deep well dish (Nunc) and 8 different compounds were tested. Cells were allowed to stand overnight before treatment with various concentrations (10-0.0003 μM) of blocking compound. Compounds diluted in medium (12 μL) were added to the cells at 37 ° C. for 10 minutes. Human MCP-1 (12 μL, R & D Diagnostics, # 279-MC) was diluted in medium and added to each well to a final concentration of 50 ng / mL. Stimulation was continued for 2 minutes at room temperature. Pre-warmed FACS Phosflow lysis / fixation buffer (1 mL, 37 ° C.) (BD Biosciences, # 558049) was added to each well. The plates were then incubated for an additional 10-15 minutes at 37 ° C. The plate was spun at 1500 rpm for 10 minutes, the supernatant was aspirated off and 1 mL of ice-cold 90% MeOH was added to each well with vigorous stirring. The plates were then incubated either at −70 ° C. overnight or on ice for 30 minutes prior to antibody staining. The plate was spun and washed twice with PBS + 2% FBS (Gibco). The wash was aspirated and the cells were suspended in the remaining buffer. Rabbit pAKT (50 μL, Cell Signaling, # 4058 L) was added at 1: 100 to each sample for 1 hour at room temperature with stirring. Cells were washed and rotated for 10 minutes at 1500 rpm. The supernatant was aspirated and the cells were suspended in the remaining buffer. The secondary antibody, goat anti-rabbit Alexa647 (50 μL, Invitrogen, # A21245) 1: 500 was added for 30 minutes at room temperature with stirring. The cells were then washed once with buffer and suspended in 150 μL buffer for FACS analysis. Cells need to be well dispersed by pipetting before flowing on flow cytometry. Cells were flowed onto LSR II (Becton Dickinson), induced forward, and side scattered to determine pAKT expression levels within the monocyte population.

Gamma counterscreen: monocyte stimulation for mouse bone marrow phosphorylated AKT expression Mouse femurs were dissected from 5 female BALB / c mice (Charles River Labs.) And collected in RPMI + 10% FBS medium (Gibco) . Mouse bone marrow was removed by cutting the distal femur by flushing 1 mL media using a 25 standard needle. The bone marrow was then dispersed in the medium using a 21 standard needle. The media volume was increased to 20 mL and cells were counted on a hemocytometer using trypan blue exclusion. The cell suspension was then increased to 7.5 × 10 ⁶ cells / 1 mL of medium and 100 μL (7.5 × 10 ⁵ cells) was aliquoted into each well of 4-96 wells, deep well dishes (Nunc) Eight different compounds were tested. Cells were allowed to stand at 37 ° C. for 2 hours before treatment with various concentrations (10-0.0003 μM) of blocking compounds. Compounds diluted in medium (12 μL) were added to bone marrow cells at 37 ° C. for 10 minutes. Mouse MCP-1 (12 μL, R & D Diagnostics, # 279-MC) was diluted with medium and added to each well to a final concentration of 50 ng / mL. Stimulation was continued for 2 minutes at room temperature. 1 mL of pre-warmed FACS Phosflow lysis / fixation buffer (BD Biosciences, # 558049) at 37 ° C. was added to each well. The plates were then incubated for an additional 10-15 minutes at 37 ° C. The plate was rotated at 1500 rpm for 10 minutes. The supernatant was aspirated off and 1 mL of ice cold 90% MeOH was added to each well with vigorous stirring. The plates were then incubated either at −70 ° C. overnight or on ice for 30 minutes prior to antibody staining. The plate was spun and washed twice with PBS + 2% FBS (Gibco). The wash was aspirated and the cells were suspended in the remaining buffer. Fc block (2 μL, BD Pharmingen, # 553140) was then added to each well for 10 minutes at room temperature. After blocking, 50 μL of primary antibody was diluted with buffer; CD11b-Alexa488 (BD Biosciences, # 557672) 1:50, CD64-PE (BD Biosciences, # 558455) 1:50, and rabbit pAKT (Cell Signaling, # 4058L) ) 1: 100 was added to each sample for 1 hour at room temperature with stirring. Wash buffer was added to the cells and spun at 1500 rpm for 10 minutes. The supernatant was aspirated and the cells were suspended in the remaining buffer. Secondary antibody; goat anti-rabbit Alex 647 (50 μL, Invitrogen, # A21245) 1: 500 was added for 30 minutes at room temperature with stirring. The cells were then washed once with buffer and suspended in 100 μL buffer for FACS analysis. Cells were run on LSR II (Becton Dickinson) and induced on CD11b / CD64 double positive cells to determine pAKT expression levels within the monocyte population.

pAKT in vivo assay Mice (transgenic 3751 female 10-12 weeks old Amgen Inc, Thousand Oaks, Calif.) are injected with anti-IgM FITC (50 μg / mouse) (Jackson Immuno Research, West Grove, PA) intravenously (0.2 mL). Fifteen minutes ago, vehicle and compound are administered by gavage (0.2 mL) by gastric tube (Oral Gabbage Needles Popper & Sons, New Hyde Park, NY). After 45 minutes, the mice are euthanized by CO ₂ chamber. Blood is drawn by cardiac puncture (0.3 mL) (1 cc 25 g syringe, Sherwood, St. Louis, Mo.) and transferred into a 15 mL conical vial (Nalge / Nunc International, Denmark). Blood is immediately fixed with 6.0 mL BD Phosflow lysis / fixation buffer (BD Bioscience, San Jose, Calif.), Inverted 3 times, and placed in a 37 ° C. water bath. Half of the spleen is removed and transferred to an Eppendorf tube containing 0.5 mL of PBS (Invitrogen Corp, Grand Island, NY). The spleen is crushed using a tissue grinder (Pellet Pestle, Kimble / Kontes, Vineland, NJ), immediately fixed with 6.0 mL BD Phosflow lysis / fixation buffer, inverted 3 times, and a 37 ° C. water bath Put in. After harvesting the tissue, the mouse is dislocated from the neck and the corpse is disposed of. After 15 minutes, the 15 mL conical vial is removed from the 37 ° C. water bath and the tissue is placed on ice until further processing. The disrupted spleen is filtered through a 70 μm cell strainer (BD Bioscience, Bedford, Mass.) Into another 15 mL conical vial and washed with 9 mL PBS. Spleen cells and blood are spun at 2,000 rpm for 10 minutes (cooling) and the buffer is aspirated. Cells are resuspended in 2.0 mL of chilled (−20 ° C.) 90% MeOH (Mallinckrodt Chemicals, Phillipsburg, NJ). Slowly add MeOH while rapidly vortexing the conical vial. The tissue is then stored at −20 ° C. until the cells can be stained for FACS analysis.

Multidose TNP Immunization On day 0 before immunization, 7-8 week old BALB / c female mice (Charles River Labs.) Were bled by eye bleeding at the retro-orbit. The blood was allowed to clot for 30 minutes and spun at 10,000 rpm in a serum microtube (Becton Dickinson) for 10 minutes. Serum was collected, aliquoted in matrix tubes (Matrix Tech. Corp.) and stored at -70 ° C until ELISA was performed. Mice were orally administered compounds before immunization and in subsequent periods based on molecular life. Then 50 μg TNP-LPS (Biosearch Tech., # T-5065), 50 μg TNP-Ficoll (Biosearch Tech., # F-1300), or 100 μg TNP-KLH (Biosearch Tech., # T-5060) + 1% alum. Mice were immunized with either (Brenntag, # 3501) in PBS. Prior to immunization, a TNP-KLH + alum solution was prepared by gently inverting the mixture for 3 hours every 10 minutes for 1 hour. On the fifth day after the final treatment, the mice were euthanized with CO ₂ and cardiac punctured. The blood was allowed to clot for 30 minutes and spun in a serum microtube at 10,000 rpm for 10 minutes. Serum was collected, aliquoted in matrix tubes, and stored at -70 ° C until further analysis was performed. Serum levels of TNP specific IgG1, IgG2a, IgG3 and IgM were then measured via ELISA. TNP-BSA (Biosearch Tech., # T-5050) was used to capture TNP-specific antibodies. TNP-BSA (10 [mu] g / mL) was used to coat 384 well ELISA plates (Corning Costar) overnight. The plates were then washed and blocked for 1 hour using 10% BSA ELISA blocking solution (KPL). After blocking, the ELISA plate was washed and serum samples / standards were serially diluted and allowed to bind to the plate for 1 hour. Plates were washed and Ig-HRP conjugated secondary antibodies (goat anti-mouse IgG1, Southern Biotech # 1070-05, goat anti-mouse IgG2a, Southern Biotech # 1080-05, goat anti-mouse IgM, Southern Biotech # 1020-05. , Goat anti-mouse IgG3, Southern Biotech # 1100-05) was diluted 1: 5000 and incubated on the plate for 1 hour. Antibodies were visualized using TMB peroxidase solution (SureBlue Reserve TMB, KPL). Plates were washed and samples were allowed to develop in TMB solution for approximately 5-20 minutes depending on Ig analysis. The reaction was stopped with 2M sulfuric acid and the plate was read at OD 450 nm.

  For the treatment of PI3Kδ-mediated diseases (such as rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases), the compounds of the present invention are administered orally, parenterally (inhalation spray) By rectal, rectal or topical administration) in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intrasternal, infusion technique or intraperitoneal.

  Treatment of diseases and disorders herein may be in need of prophylactic treatment, eg, subjects such as rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases, and autoimmune diseases It is intended to include prophylactic administration of a compound of the invention, a pharmaceutical salt thereof, or any pharmaceutical composition (ie, an animal, preferably a mammal, most preferably a human).

  Administration regimens for the treatment of PI3Kδ-mediated diseases, cancer, and / or hyperglycemia using compounds of the present invention and / or compositions of the present invention may vary depending on various factors (type of disease, patient age, weight, sex, etc. , Medical condition, severity of condition, route of administration, and the particular compound used). Thus, the dosage regimen can vary widely, but can be determined routinely using standard methods. In the use of all methods disclosed herein, about 0.01 mg to 30 mg / kilogram body weight / day, preferably about 0.1 mg to 10 mg / kg, more preferably about 0.25 mg to 1 mg / kg. Dosage levels are useful.

  The pharmaceutically active compounds of the present invention can be processed according to conventional methods in pharmacy to produce medicinal products for administration to patients (such as humans and other mammals).

  Pharmaceutical compositions for oral administration can be, for example, in capsule, tablet, suspension, or liquid form. The pharmaceutical composition is preferably made up in a dosage unit form containing a predetermined amount of the active ingredient. For example, they may contain an amount of active ingredient of about 1-2000 mg, preferably about 1-500 mg, more preferably about 5-150 mg. Suitable daily doses for humans or other mammals can vary widely depending on the condition of the patient and other factors, but can again be determined using routine methods.

  The active ingredient can also be administered by injection as a composition with a suitable carrier, such as saline, dextrose, or water. The daily parenteral dosage regimen is about 0.1 to about 30 mg / kg total body weight, preferably about 0.1 to about 10 mg / kg, and more preferably about 0.25 mg to 1 mg / kg.

  Injectable preparations (such as sterile injectable aqueous or hydrophobic suspensions) may be prepared according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic, parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution, among others. In addition, sterile, fixed oils are conventionally used as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids (such as oleic acid) find use in injectable preparations.

  Suppositories for rectal administration of drugs are suitable non-irritating excipients (such as cocoa butter and polyethylene glycol) that melt at the rectum and release the drug because they are solid at room temperature but liquid at rectal temperature It can be prepared by mixing drugs.

  A suitable topical dose of the active ingredient of the compounds of the invention is 0.1 mg to 150 mg administered 1 to 4 times a day, preferably once or twice. Active ingredients for topical administration may comprise 0.001% to 10% w / w, for example 1% to 2% weight of the formulation, and may contain as much as 10% w / w, but preferably 5% w / w w or less, more preferably 0.1% to 1% of the formulation.

  Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for skin permeation (eg, coatings, lotions, ointments, creams or muds) and drops suitable for ophthalmic, ear or nasal administration. Can be mentioned.

  The compounds of the invention for administration are originally used in combination with one or more adjuvants appropriate for the designated route of administration. Compounds include lactose, sucrose, starch powder, cellulose esters of alkanoic acid, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfuric acid, acacia, gelatin, sodium alginate, polyvinyl-pyrrolidine, And / or may be mixed with polyvinyl alcohol and may be tableted or encapsulated for conventional administration. Alternatively, the compounds of the invention can be dissolved in saline, water, polyethylene glycol, propylene glycol, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and / or various buffers. Other adjuvants and dosage forms are well known in the pharmaceutical art. The carrier or diluent may include time delay materials (such as glyceryl monostearate or glyceryl distearic acid) alone or in combination with waxes or other materials well known in the art.

  The pharmaceutical composition may be made in a solid form (such as a granule, powder or suppository), or in a liquid form (eg, a solution, suspension, or emulsion). The pharmaceutical composition can be subjected to conventional pharmaceutical operations (such as sterilization) and / or can include conventional adjuvants (such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc.).

  Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one of an inert diluent such as sucrose, lactose, or starch. Such dosage forms can also contain additional substances other than inert diluents, such as a lubricant (such as magnesium stearate), as a normal practice. In the case of capsules, tablets, and pills, the dosage forms can also include buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

  Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents (such as water) commonly used in the art. obtain. Such compositions may also contain adjuvants such as wetting agents, sweetening agents, flavoring agents, and flavoring agents.

  The compounds of the invention can have one or more asymmetric carbon atoms and can therefore exist in the form of optical isomers as well as their racemic or non-racemic mixtures. Optical isomers can be obtained by decomposing racemic mixtures according to conventional processes, for example by salt formation of diastereoisomers, by treatment with optically active acids or bases. Examples of suitable acids are tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, and camphorsulfonic acid, and then a mixture of diastereoisomers is separated by crystallization and then optically active from these salts. Free base. Different separation processes of optical isomers include the use of chiral chromatography columns that are optimally selected to maximize the separation of enantiomers. Yet another available method includes the synthesis of covalent diastereoisomeric molecules by reacting an active form of an optically pure acid or optically pure isocyanate with a compound of the invention. It is. The synthesized diastereoisomers can be separated by conventional means (such as chromatography, distillation, crystallization or sublimation) and then hydrolyzed to deliver the enantiomerically pure compound. Optically active compounds of the invention can be obtained analogously by using active starting materials. These isomers can be in the free acid, free base, ester or salt form.

  Similarly, the compounds of the present invention may exist as isomers, compounds that have the same molecular formula but different atomic arrangements. In particular, the alkylene substituents of the compounds of the invention are normally and preferably arranged and inserted into the molecule as shown in the definition of each of these groups read from left to right. However, one of ordinary skill in the art will appreciate that in some cases, compounds of the present invention can be prepared in which these substituents are reversely oriented with respect to other atoms in the molecule. That is, the substituent to be inserted can be the same as described above except that it is inserted in the molecule in the reverse orientation. Those skilled in the art will appreciate that these isomeric forms of the compounds of the invention are intended to be included within the scope of the invention.

  The compounds of the invention can be used in the form of salts derived from inorganic or organic acids. Salts include, but are not limited to: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, disulfate, butyrate, camphorate, Camphorsulfonate, digluconate, cyclopentanepropionate, dodecyl sulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloric acid Salt, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamo Acid, pectate, persulfate, 2-phenylpropionate, picrate, pivalate, propionate, succinate, liquor Salt, thiocyanate, tosylate, mesylate and undecanoate. In addition, basic nitrogen-containing groups include lower alkyl halide compounds (such as methyl, ethyl, propyl, and butyl chloride, bromide, and iodide); dialkyl sulfates (such as dimethyl, diethyl, dibutyl, and diamyl sulfate), It can be quaternized with long chain halogen compounds (such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halogen compounds (such as benzyl and phenethyl bromides). Thereby aqueous or oily or dispersion products are obtained.

  Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids (such as hydrochloric acid, sulfuric acid and phosphoric acid) and organic acids (such as oxalic acid, maleic acid, succinic acid and citric acid). It is done. Other examples include alkali metal salts or alkaline earth metal (such as sodium, potassium, calcium or magnesium) salts or organic base salts.

Also included within the scope of the invention are pharmaceutically acceptable esters of carboxylic acid or hydroxyl containing groups, including metabolically labile ester or prodrug forms of the compounds of the invention. A metabolically labile ester is one that, for example, can increase the blood level of the corresponding non-esterified form of the compound and prolong its effectiveness. Prodrug forms are those that are not active forms of the molecule upon administration but are therapeutically activated after some in vivo activity or biotransformation (such as metabolic effects), eg, enzymatic or hydrolytic cleavage. For a general discussion of prodrugs involving esters, see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985). Examples of masked carboxylate anions include alkyl (eg, methyl, ethyl), cycloalkyl (eg, cyclohexyl), aralkyl (eg, benzyl, p-methoxybenzyl), alkylcarbonyloxyalkyl (eg, pivalo And various esters such as (Iloxymethyl). Amines are masked as arylcarbonyloxymethyl substituted derivatives. Arylcarbonyloxymethyl substituted derivatives are cleaved in vivo by esterases to release free drug and formaldehyde (Bungaard J. Med. Chem. 2503 (1989)). In addition, drugs containing acidic NH groups such as imidazole, imide and indole are masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups are masked as esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich base hydroxamic acid prodrugs, their preparation and use. Esters of the compounds of the present invention can include, for example, methyl, ethyl, propyl, and butyl esters, as well as other suitable esters formed between an acidic moiety and a hydroxyl group-containing moiety. Examples of metabolically unstable esters include groups such as methoxymethyl, ethoxymethyl, iso-propoxymethyl, α-methoxyethyl, α-((C ₁ -C ₄ ) alkyloxy) ethyl, such as methoxyethyl, ethoxy Ethyl, propoxyethyl, iso-propoxyethyl, etc .; 2-oxo-1,3-dioxolen-4-ylmethyl group (such as 5-methyl-2-oxo-1,3, dioxolen-4-ylmethyl); C ₁ -C ₃ alkylthiomethyl groups such as methylthiomethyl, ethylthiomethyl, isopropylthiomethyl and the like; acyloxymethyl groups such as pivaloyloxymethyl, α-acetoxymethyl and the like; ethoxycarbonyl-1-methyl; or α-acyloxy-α -Substituted methyl groups such as α-acetoxyethyl may be mentioned .

  In addition, the compounds of the present invention may exist as crystalline solids that can be crystallized from common solvents (ethanol, N, N-dimethyl-formamide, water, etc.). Accordingly, the crystalline forms of the compounds of the invention may exist as polymorphs, solvates and / or hydrates of the parent compound or pharmaceutically acceptable salts thereof. All such forms are similarly contemplated within the scope of the present invention.

  While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered in combination, the therapeutic agents can be formulated as separate compositions that are administered at the same or different times, or the therapeutic agents can be administered as a single composition.

  The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes apparent to those skilled in the art are intended to be within the scope and nature of the invention as defined in the appended claims.

  From the foregoing details, those skilled in the art can readily ascertain the essential features of the present invention and adapt the various features of the present invention to adapt to various uses and conditions without departing from the spirit and scope thereof. Changes and modifications can be made.

Claims (4)

Or a pharmaceutically acceptable salt thereof, wherein:
X ² is C (R ⁴ ) or N;
X ³ is C (R ⁵ ) or N;
X ⁴ is C (R ⁵ ) or N;
X ⁵ is C (R ⁴ ) or N; more than ^{two of} said X ² , X ³ , X ⁴ and X ⁵ are not N;
Y is NR ⁷ , CR ^a R ^a , S or O;
n is 0, 1, 2 or 3;
R ¹ is H, halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O ) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^{a) C (= O) OR} a, -N (R a) ^{(= O) NR a R a} , -N (R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a , —NR ^a C _2-6 alkyl OR ^a , —NR ^a C _2-6 alkyl CO ₂ R ^a , —NR ^a C _{2 6} alkyl _{^{SO 2 R b, -CH 2 C}} (= O) R a, -CH 2 C (= O) OR a, -CH 2 C (= O) NR a R a, -CH 2 C (= NR ^a ) NR ^a R ^a , —CH ₂ OR ^a , —CH ₂ OC (═O) R ^a , —CH ₂ OC (═O) NR ^a R ^a , —CH ₂ OC (═O) N (R ^a ) _{^{S (= O) 2 R a}} , -CH 2 OC 2~6 alkyl _{^{NR a R a, -CH 2 OC}} 2~6 alkyl _{^{OR a, -CH 2 SR a,}} - _{^{H 2 S (= O) R}} a, -CH 2 S (= O) 2 R b, -CH 2 S (= O) 2 NR a R a, -CH 2 S (= O) 2 N (R a) C (═O) R ^a , —CH ₂ S (═O) ₂ N (R ^a ) C (═O) OR ^a , —CH ₂ S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —CH ₂ NR ^a R ^a , —CH ₂ N (R ^a ) C (═O) R ^a , —CH ₂ N (R ^a ) C (═O) OR ^a , —CH ₂ N (R ^a ) C (═O) NR ^a R ^a , —CH ₂ N (R ^a ) C (═NR ^a ) NR ^a R ^a , —CH ₂ N (R ^a ) S (═O) ₂ R ^a , —CH ₂ N (R ^a ) S (═O) ₂ NR ^a R ^a , —CH ₂ NR ^a C _2-6 alkyl NR ^a R ^a , —CH ₂ NR ^a C _2-6 alkyl OR ^a , —CH ₂ NR ^a C _2-6 alkyl CO ₂ R ^a and —CH ₂ NR ^a C _2-6 alkyl SO ₂ R ^b ; or R ¹ is selected from 0, 1, 2, 3 or 4 selected from N, O and S Includes atoms but no more than one O or S atom, direct bond, C _1-4 alkyl bond, OC _1-2 alkyl bond, C _1-2 alkyl O bond, N (R ^a ) bond Or O-linked saturated, partially saturated or unsaturated 3, 4, 5, 6 or 7-membered monocyclic or 8, 9, 10 or 11-membered bicyclic, halo, C _1-6 alkyl, C _1-4 haloalkyl , Cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , ^{-OC (= O) R a,} -OC (= O) NR a R a, -OC (= O _{^{N (R a) S (=}} O) 2 R a, -OC 2~6 alkyl _^NR a ^R _{a, -OC} ^2~6 alkyl ^{OR a, -SR a, -S (} = O) R a, -S ( ═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (═NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (═O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 0,1 independently selected from alkyl OR ^a, Or substituted by 3 substituents, where available carbon atoms of the ring are additionally substituted by 0, 1 or 2 oxo or thioxo groups, and the ring is additionally phenyl, pyridyl, pyrimidyl Substituted by 0 or 1 direct bond selected from morpholino, piperazinyl, piperazinyl, pyrrolidinyl, cyclopentyl, cyclohexyl, SO ₂ bond, C (═O) bond or CH ₂ bond group, all of which are further halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R substituted by 0, 1, 2, or 3 groups selected from: ^a , —NR ^a R ^a , and —N (R ^a ) C (═O) R ^a ;
R ² is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S ( ═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , _{^{-S (= O) 2 NR a}} R a, -S (= O) 2 N (R a) C (= O) R a, -S (= O) 2 N (R a) C (= O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) ^{C (= O) OR a,} -N (R a) C ( ^{O) NR a R a, -N} (R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) Selected from ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ³ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but no more than 1 O or S, saturated, partially saturated or unsaturated 5 , 6 or 7 membered monocyclic ring or 8, 9, 10 or 11 membered bicyclic ring, wherein available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, Substituted with 0 or 1 R ² substituents, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S ( ═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a independently selected from 0, 1, 2, or 3 substituents Further substituted; or R ³ is , Halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (= NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S ( ═O) ₂ NR ^a R ^a , —S (═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , − S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (= ^{O) OR a, -N (R} a) C (= O) ^{R a R a, -N (R} a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) 2 NR ^{selected from a} R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ⁴ is independently in each case H, halo, nitro, cyano, C _1-4 alkyl, OC _1-4 alkyl, OC _1-4 haloalkyl, NHC _1-4 alkyl, N (C _{1-4 alkyl) C 1 to 4 alkyl, C (= O) NH 2} , C (= O) NHC 1~4 _{alkyl, C (= O) N (} C 1~4 _{alkyl) C 1 to 4} alkyl, N (H) C (═O) C _1-4 alkyl, N (C _1-4 alkyl) C (═O) C _1-4 alkyl, C _1-4 haloalkyl, or 0 selected from N, O and S, Unsaturated 5, 6 or 7-membered monocycle containing 1, 2, 3 or 4 atoms, but no more than 1 O or S, halo, C _1-4 alkyl, C _{1 -3} haloalkyl, -OC _1-4 alkyl, -NH ₂ , -NHC _1-4 alkyl , It is substituted by 0, 1, 2 or 3 substituents selected from -N _{(C 1 to 4 alkyl) C 1 to 4} alkyl;
R ⁵ is independently in each case H, halo, nitro, cyano, C _1-4 alkyl, OC _1-4 alkyl, OC _1-4 haloalkyl, NHC _1-4 alkyl, N (C _1-4 Alkyl) C _1-4 alkyl or C _1-4 haloalkyl;
R ⁶ contains 0, 1, 2, 3 or 4 atoms selected from N, O and S, but no more than 1 O or S, saturated, partially saturated or unsaturated 5 , 6 or 7 membered monocyclic ring or 8, 9, 10 or 11 membered bicyclic ring, wherein available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, Substituted with 0 or 1 R ² substituents, the ring is halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (═O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , —S (═O) ₂ NR ^a R ^a , —S ( ═O) ₂ N (R ^a ) C (═O) R ^a , —S (═O) ₂ N (R ^a ) C (═O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C (═O) OR ^a , —N (R ^a ) C (═O) NR ^a R ^a , —N (R ^a ) C (= NR ^a ) NR ^a R ^a , —N (R ^a ) S (═O) ₂ R ^a , —N (R ^a ) S (= O) ₂ NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a independently selected from 0, 1, 2, or 3 substituents Further substituted; or R ⁶ is , H, halo, C _1-6 alkyl, C _1-4 haloalkyl, cyano, nitro, —C (═O) R ^a , —C (═O) OR ^a , —C (═O) NR ^a R ^a , —C (═NR ^a ) NR ^a R ^a , —OR ^a , —OC (═O) R ^a , —OC (═O) NR ^a R ^a , —OC (═O) N (R ^a ) S (= O) ₂ R ^a , —OC _2-6 alkyl NR ^a R ^a , —OC _2-6 alkyl OR ^a , —SR ^a , —S (═O) R ^a , —S (═O) ₂ R ^a , — S (= O) ₂ NR ^a R ^a , -S (= O) ₂ N (R ^a ) C (= O) R ^a , -S (= O) ₂ N (R ^a ) C (= O) OR ^a , —S (═O) ₂ N (R ^a ) C (═O) NR ^a R ^a , —NR ^a R ^a , —N (R ^a ) C (═O) R ^a , —N (R ^a ) C ^{(= O) OR a, -N} (R a) C (= ^{) NR a R a, -N (} R a) C (= NR a) NR a R a, -N (R a) S (= O) 2 R a, -N (R a) S (= O) 2 Selected from NR ^a R ^a , —NR ^a C _2-6 alkyl NR ^a R ^a and —NR ^a C _2-6 alkyl OR ^a ;
R ⁷ is H, C _1-6 alkyl, —C (═O) N (R ^a ) R ^a , —C (═O) R ^b, or C _1-4 haloalkyl;
R ^a is independently at each occurrence H or R ^b ; and R ^b is independently at each _occurrence phenyl, benzyl or C _1-6 alkyl, phenyl, benzyl and C _{1 6} alkyl, _{halo, C 1 to 4 alkyl, C 1 to 3 haloalkyl, -OC 1 to 4 alkyl,} -NH 2, _{-NHC 1 to 4} alkyl, -N _{(C 1 to 4 alkyl) C 1 to 4} Substituted with 0, 1, 2 or 3 substituents selected from alkyl,
A compound or any pharmaceutically acceptable salt thereof.   Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, psoriatic arthritis, psoriasis, inflammatory diseases and autoimmune diseases, inflammatory bowel disorders, inflammatory eye disorders, inflammation or unstable bladder disorders comprising administering a compound according to claim 1 , Skin disease with inflammatory component, chronic inflammatory condition, autoimmune disease, systemic lupus erythematosus (SLE), myasthenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiple Methods for treating sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions and hypersensitivity.   12. A method of treating cancer comprising mediated by, or associated with, p110δ activity comprising administering a compound according to claim 1.   A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable diluent or carrier.